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1 
1 Abstract  
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype in 
the western world. In Finland, 600 new patients are diagnosed with DLBCL 
annually. DLBCL is an aggressive disease and rapidly fatal if left untreated. The 
treatment of B-cell malignancies has been revolutionized over the past few decades 
by the induction of monoclonal CD20-antibody rituximab.  Approximately 70% of 
the patients can now be cured with combination of anthracycline-based 
chemotherapy and rituximab.  
Genome-wide expression profile (GEP) studies have revealed that DLBCL 
comprises several distinct molecular subgroups, which differ in the expression of 
specific gene signatures and also in the oncogenic pathways that appear to be 
involved, often corresponding to discrete prognostic categories. Nevertheless, 
clinical risk factors remain as a cornerstone of the treatment decisions and prognosis. 
Research on biological prognostic factors and targeted therapies is active and it is 
likely that in the near future the patients will be treated according to risk-adapted 
and biomarker driven therapies. 
The aim of this study was to identify novel prognostic factors in the 
immunochemotherapy era. The study population consisted of tumour tissue, blood 
samples and the clinical data of DLBCL patients treated with chemotherapy and 
immunochemotherapy.  The patients were treated in cancer centers in Finland and in 
other Nordic countries. In addition, the gene expression data generated in the 
Lymphoma/Leukemia Molecular Profiling Project (LLMP) and Cancer Genome 
Characterization Initiative (CGCI) were used. 
In the first substudy, we examined the association of protein kinase C β II (PKCβII) 
expression with survival. PKCβII is an enzyme involved in cellular proliferation and 
it is often overexpressed in cancer, including DLBCL. The expression of PKCβII by 
immunohistochemistry was evaluated in 98 DLBCL tumour samples. When the 
PKCβII expression data was combined with the clinical information, we observed 
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that the patients with high expression had significantly poorer OS than the patients 
with low expression. The immunohistochemical results were validated using the 
gene expression data from tumour samples of 233 patients. Consistently, high 
PKCβII gene expression correlated with inferior treatment outcome. 
PKCβII is also known for its ability to stimulate tumour angiogenesis. Abundant 
vasculature in the tumour is associated with inferior survival in various 
malignancies. We determined the microvessel density (MVD) in 76 tumour samples 
collected prior to immunochemotherapy. No association between MVD and survival 
was found when the results were correlated with the survival data. 
We next analysed the association of serum VEGF levels with survival in DLBCL 
patients. Vascular endothelial growth factor (VEGF) is a signalling protein which 
stimulates vasculogenesis and angiogenesis. It is overexpressed in cancer tissue and 
essential in tumour growth and development. VEGF levels in the serum of 102 
DLBCL patients were measured. The serum samples were collected at the time of 
diagnosis before the patients had been treated with dose-dense 
immunochemotherapy in the Nordic phase II trial. The exon array data of 38 patients 
in the trial was also used to measure VEGF mRNA levels in the tumour tissue. We 
observed that high serum VEGF levels are associated with inferior survival after 
therapy. However, VEGF mRNA levels correlated neither with the survival nor the 
serum VEGF levels. Thus, it is possible that the serum VEGF is not derived from 
the tumour itself but may be a host response instead. 
As tumour associated macrophages (TAMs) reprogrammed by tumour cells are 
known to serve as a major source of angiogenic factors promoting angiogenesis, we 
next analysed the association of TAMs with the survival. Also, it is known that the 
mechanism of rituximab is partly mediated by tissue-resident macrophages. The 
function of TAMs is known to be controversial as they have both anti-tumour and 
pro-tumour features. In this study several patient sets and both 
immunohistochemistry and gene expression data were used. In the patients treated 
with chemotherapy, high TAM levels in tumour tissue served as an adverse 
prognostic marker. When the tumour samples of the patients treated with 
immunochemotherapy were analysed, the effect of TAMs was opposite: high TAM 
content was associated with favourable outcome. This may be caused by the 
mechanism of action of rituximab through macrophages. 
Finally, we measured the serum levels of chemokine CCL18 and CD163, proteins 
commonly expressed in M2 type macrophages, from the serum samples of 105 
DLBCL patients. Serum samples were collected prior to immunochemotherapy. 
From 45 patients, samples collected after three treatment cycles was also available. 
When the results were correlated with the clinical data, a significant association with 
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inferior survival and low CCL18 serum levels was observed. Interestingly, the 
correlation with low serum CCL18 level and adverse survival was also found in 
serum samples collected after three treatment cycles. Similar trend was observed 
with s-CD163 levels and survival. 
To summarize, high PKCβII expression and low TAM content in the tumour as well 
as high serum VEGF and low serum CCL18 levels serve as prognostic factors for 
inferior outcome in immunochemotherapy-treated DLBCL. Their use as prognostic 
biomarkers in the clinical setting, however, calls for further study. Combined, the 
results underline the complex biology of DLBCL and the interplay between the 
tumour microenvironment, host responses and the malignant cells.  
1.1 Tiivistelmä suomeksi 
Diffuusi suurisoluinen B-solulymfooma (DLBCL) on yleisin imusolmukesyöpä 
länsimaissa. Suomessa siihen sairastuu 600 ihmistä vuosittain. DLBCL on 
aggressiivinen tauti, joka hoitamattomana johtaa kuolemaan. B-solulymfoomien 
hoito on mullistunut viimeisen parinkymmenen vuoden aikana. Jo 
seitsemänkymmentäluvulla julkaistiin ensimmäiset tutkimukset, joissa DLBCL 
pystyttiin parantamaan täysin monisolunsalpaajahoidolla. Hoito tehosi kuitenkin 
vain alle puolella potilaista ja loput menehtyivät. Vuosituhannen vaihde toi 
monoklonaaliset vasta-aineet syövänhoitoon ja tämä on parantanut DLBCL:n 
ennustetta huomattavasti. Nykyhoidolla, jossa yhdistetään monisolunsalpaajahoitoon 
rituksimabi, monoklonaalinen vasta-aine B-solun pinnalla esiintyvää CD20-
antigeeniä vastaan, saadaan parannettua noin 70 % potilaista. 
Geenisirututkimukset ovat paljastaneet, että sen sijaan että DLBCL olisi yksittäinen 
tauti, se on heterogeeninen ryhmä tauteja, jotka ilmentävät eri tavoin B-solun 
kypsymisvaiheita ja myös kasvaimen mikroympäristöön ja potilaan ominaisuuksiin 
liittyviä tekijöitä. DLBCL voidaan jakaa geeniekspressioprofiilin perusteella 
lymfoomasolun alkuperän mukaisiin alaryhmiin, ja lisäksi nähdään eroja 
syöpäsolujen mikroympäristöön, signaalireitteihin ja mutaatioihin liittyvissä 
tekijöissä. Näillä tekijöillä on merkitystä myös hoitovasteeseen ja ennusteeseen. 
Tulevaisuuden haaste DLBCL-potilaiden hoidossa on ymmärtää näitä 
eroavaisuuksia paremmin ja kohdentaa hoitoja yksilöllisemmin niin, että yhä 
useampi potilas paranisi taudistaan. Noin 30 %:lla DLBCL:aa sairastavista potilaista 
tauti ei parane nykyhoidolla.  Keskeinen tavoite on näiden potilaiden varhainen 
tunnistaminen ja uusien biologisten lääkkeiden kohdentaminen niistä hyötyville.  
Tämän väitöskirjatyön tavoitteena oli selvittää DLBCL:n eri ennustetekijöitä ja 
peilata niitä ennusteeseen ennen ja jälkeen rituksimabin käyttöönoton.  
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Ensimmäisessä osatyössä tutkittiin proteiinikinaasi C β II:n (PKCβII) ilmentymisen 
merkitystä DLBCL:n ennusteseen. PKCβII on solusignaloinnin entsyymi, jolla on 
olennainen merkitys proliferaatiossa ja myös verisuonten uudismuodostuksessa. Sen 
yli-ilmentymistä on havaittu useissa syöpäkasvaimissa ja yleensä tämä on myös 
yhteydessä huonoon ennusteeseen. Tutkimuksessa mitattiin PKCβII-ekspressiota 98 
DLBCL-potilaan kasvainnäytteessä ja verrattiin tuloksia diagnoosivaiheen kliinisiin 
tietoihin sekä seurantatietoihin. Potilailla, joiden kasvainkudos ilmensi paljon 
PKCβII:tä, oli tilastollisesti merkitsevästi huonompi ennuste kuin niillä, joilla 
PKCβII-tasot olivat alhaiset. Validointiaineistona käytettiin vielä 233 
immunokemoterapiahoidetun potilaan geeniekspressiotietoja ja sama päti myös tässä 
aineistossa: potilailla, joilla oli korkeammat PKCβII-mRNA-tasot, myös ennuste oli 
huonompi. 
Verisuonten uudismuodostus eli angiogeneesi on yksi syöpäkasvaimen 
tunnusmerkeistä. PKCβII:n tiedetään edistävän angiogeneesiä. Myös 
kasvainkudoksen mikroverisuonien määrä (MVD) korreloi huonon ennusteen kanssa 
monessa maligniteetissä. Määritimme CD31-vasta-aineen avulla 
immunohistokemiallisesti MVD:n 76 kasvainnäytteestä ja vertasimme niitä 
potilaiden seurantatietoihin. Potilaat oli hoidettu immunokemoterapialla. 
Korrelaatiota tautivapaaseen elinaikaan tai kokonaiselinaikaan ei löytynyt.  
Angiogeneesin tunnetuimpia ja tärkeimpiä säätelijöitä sekä terveessä että malignissa 
kudoksessa on verisuonikasvutekijä VEGF (vascular endothelial growth factor). 
VEGF on tärkeä hoidon kohde ja sen runsas ilmentyminen on huonon ennusteen 
merkki monissa maligniteeteissa. VEGF:n vaikutuksesta kasvaimeen muodostuu 
verisuonia. Toisessa osatyössä tutkittiin VEGF:n ennusteellista merkitystä 
DLBCL:ssä. 102 DLBCL-potilaan verestä mitattiin VEGF-pitoisuus ennen 
syöpähoidon aloitusta. Potilasaineistona käytettiin Pohjoismaisen Lymfoomaryhmän 
NLC-LBC-04-tutkimuksen potilaita. Potilaat saivat korkean riskin DLBCL:n 
hoidoksi 6 R-CHOEP-hoitoa ja keskushermostoprofylaksian. Niillä potilailla, joilla 
seerumin VEGF-taso oli korkea ennen hoidon aloitusta, oli selvästi huonompi 
ennuste kuin potilailla, joilla tasot olivat alhaisemmat. Kasvaimen VEGF-mRNA-
tasot eivät sen sijaan korreloineet ennusteen kanssa. Geeniekspressio ei myöskään 
korreloinut VEGF-seerumitasojen kanssa. 
Kasvainkudoksen makrofageilla on kaksoisrooli syöpäkasvaimen etenemisessä; sekä 
syöpäkasvua hillitsevä että syöpää edistävä vaikutus. Syöpäsolut voivat rekrytoida 
makrofagit tietyillä signaaleilla edistämään syövän kasvua. Perinteisesti suurta 
makrofagipitoisuutta syöpäkasvaimessa on pidetty huonon ennusteen merkkinä 
monissa syövissä. Makrofagit ovat myös mukana syövän verisuoniston 
uudismuodostuksessa. Tiedetään myös, että rituksimabin vaikutusmekanismissa 
makrofageilla on tärkeä rooli. Tämän takia kolmannessa osatyössä tutkittiin 
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kasvaimen makrofagien määrän ennusteellista merkitystä immunokemoterapia-
hoidetuilla DLBCL-potilailla. Potilasaineistoja oli useita ja jälleen menetelminä oli 
sekä immunohistokemia että geeniekspressiotasojen määritys. Makrofagit 
tunnistettiin immunohistokemiallisesti CD68-vasta-aineella ja CD68-positiivisten 
solujen määrä suhteutettiin kliinisiin tietoihin. Niiden immunokemoterapialla 
hoidettujen potilaiden, joiden kasvainnäytteissä oli runsaasti makrofageja, ennuste 
oli parempi kuin potilaiden, joilla makrofageja oli vähän. Jos taas hoito oli annettu 
ennen immunokemoterapia -aikakautta, suuri makrofagien lukumäärä oli huonon 
ennusteen merkki. Sama havaittiin kun verrattiin CD68:n mRNA-tasoja 
kasvaimessa. Tulosten perusteella on mahdollista, että rituksimabin vaikutukset 
välittyvät ainakin osittain makrofagien kautta. 
Lopuksi mittasimme CCL18 ja CD163 -tasoja 105 potilaan verestä. CCL18 ja 
CD163 ovat proteiineja, joita käytetään M2-tyypin makrofagien tunnistamiseen. 
Näytteet oli kerätty ennen immunokemoterapian aloitusta ja 45 potilaasta oli 
saatavilla myös kolmen hoidon jälkeinen verinäyte. Kun mittaustuloksia analysoitiin 
kliinisten tietojen kanssa, huomattiin että matalat CCL18-tasot sekä ennen hoitoa 
otetuissa että hoidon jälkeisissä seeruminäytteissä korreloivat huonon ennusteen 
kanssa.  
Yhteenvetona voidaan todeta, että sekä kasvainkudoksen korkea PKCβII-ekspressio 
ja matala makrofagimäärä että verinäytteestä mitattu korkea VEGF- ja matala 
CCL18-pitoisuus ovat huonon ennusteen merkkejä immunokemoterapialla 
hoidetuilla DLBCL-potilailla. Lisätutkimukset suuremmilla potilasaineistoilla ovat 
välttämättömiä, ennen kuin näitä ennustetekijöitä voidaan käyttää potilastyössä. 
Tulokset heijastavat DLBCL:n heterogeenisyyttä ja korostavat malignien solujen ja 
kasvaimen mikroympäristön monimutkaista vuorovaikutusta.  
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2 
2 Introduction 
Cancer is a disease defined by the ability of a malignant cell to grow and multiply in 
an uncontrolled fashion and the ability of these cells to migrate from the original site 
and spread to distant site. The progressive understanding of the molecular 
mechanisms of cancer and the introduction of new targeted therapies has 
revolutionized the treatment and prognosis of many cancers in the last few decades. 
In the ground-breaking paper, Hanahan and Weinberg described the hallmarks of 
cancer comprising of six different corner stones: cancer cells evade apoptosis, are 
self-sufficient in growth signals and insensitive to anti-growth signals, can sustain 
angiogenesis, have limitless replicative potential, and can invade to other tissues and 
metastasize (Hanahan et Weinberg, 2001). Recently, also genomic instability in 
cancer cells, tumour-promoting inflammation, reprogramming energy metabolism 
and evading immune destruction have been added to the list (Hanahan et Weinberg, 
2011). Slowly, the knowledge of the biology is transforming into clinical therapies. 
Lymphoid malignancies are a group of cancers originating from the lymphatic cells 
of the immune system and occur as a solid tumour of lymphoid cells. Lymphoma 
comes in plethora of different types and forms and the clinical picture varies from 
indolent diseases to very aggressive types. Current classification includes over 70 
lymphoma entities. Diffuse large B-cell lymphoma (DLBCL) is the most common 
lymphoma type in western countries comprising about 40% of the cases. Depending 
on the stage of the disease, 50–80% of DLBCL patients can be cured with 
contemporary therapies comprising immunotherapy and chemotherapy. Despite 
these advances in therapy over the last decade, about one third of patients do not 
respond to therapy and ultimately die from the disease. Clinical decisions are still 
mainly based on clinical features. Gene expression profiling (GEP) studies and 
immunohistochemistry have revealed that DLBCL is a heterogeneous group of 
diseases rather than one homogenous entity. GEP studies have emphasized the 
importance of tumour microenvironment in the prognosis and the treatment outcome 
of the patients. Angiogenesis, the formation of new blood vessels, and tumour 
associated macrophages are of a particular interest because they are the target of 
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various new anticancer treatments. Despite this knowledge of the heterogeneity of 
the disease, the treatment choices are still mainly done according to clinical factors. 
The challenge of lymphoma care is to integrate the molecular algorithms into 
clinical practice, and ultimately to cure more patients. 
This doctoral thesis aims to give a brief overview on what we now know about the 
biological base and the prognostic factors of diffuse large cell lymphoma, discuss 
the role of tumour microenvironment and angiogenesis in the prognosis of the 
disease, and introduce novel biological prognostic factors. 
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3 
3 Review of the literature 
3.1 B-Cell differentiation and lymphoma pathogenesis 
Lymphomas are a group of cancers that originate from the lymphatic cells of the 
immune system and occur as a solid tumour of lymphoid cells in the lymphatic 
system or elsewhere in the body. The adaptive immune system is particularly 
susceptible to malignant transformation leading to cancer for several reasons. The 
cells of the immune system have the ability to multiply rapidly upon stimulation, 
even after long periods in a dormant, non-dividing state. In addition, B-cells are able 
to mutate their DNA to further enhance specificity against the pathogen. This 
enables the immune system to fight against a large variety of pathogens. 
Consequently, the mechanisms that drive normal B-cell differentiation and 
activation are exploited by B-cell lymphomas for their unlimited growth and 
survival. The signalling pathways that normal B-cells utilize to recognize antigens 
are frequently distorted in B-cell malignancies, leading to constitutive activation of 
pro-survival pathways. 
B-cell malignancies are associated with distinct stages of B-cell development. Naïve 
B-cells mature through transformation and proliferation into antibody-producing 
plasma-cells and memory cells. The B-cell receptor (BCR) and its precursor (pre-
BCR) control B-cell homeostasis, differentiation and function, and aberrant pre-
BCR and BCR signalling have a central role in B-cell neoplasia. (Rickert 2013, 
Swerdlow et al. 2008 Armitage et al. 2010) The stages of differentiation and 
neoplasms associated are represented in Figure 1. 
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Figure 1. B-cell maturation and corresponding lymphoma phenotypes.  (modified Wiegert et al. 
2012 and Rickert 2013) (CLL=chronic lymphocytic leukemia, MZL=marginal zone lymphoma, 
MCL=mantle cell lymphoma, BL_Burkitt lymphoma, GCB DLBCL=germinal center DLBCL, 
FL=follicular lymphoma, ABC DLBCL =activated B-cell DLBCL, MM=multiple myeloma) 
3.2 Lymphoma classifications 
Thomas Hodgkin published the first description of lymphoma in 1832. Since then, 
many other forms of lymphoma have been identified and described, grouped under 
several proposed classifications. 
The first attempt to classify lymphoma types was made by Henry Rappaport in 
1956. The Rappaport classification, comprising only three distinct lymphoma 
entities, was developed before lymphoid cells were divided into B- and T-cells. 
Classification with the distinction of B- and T-cell lymphomas was published by 
Lukes and Collins in 1974. In 1978, Kiel classified lymphomas according to low and 
high grade malignancy. The 1982 Working formulation´s goal was to find 
concordance between Lukes–Collins and Kiel classifications. Working Formulation 
also introduced the non-Hodgkin lymphoma (NHL) category, divided into 16 
different diseases. However, because NHLs have little in common with each other 
and the NHL label is of limited benefit to a clinician, this classification is slowly 
being abandoned. REAL (Revised European-American Lymphoma) classification, 
published in 1994, combined the former classifications. However, it was not based 
on the histogenesis of lymphoma cells, rather it presented a list of well-defined 
clinicopathological entities.  
 10 
 
 
The latest classification by the WHO (2008, revised 2016) lists over 70 different 
forms of lymphoma divided in several groups. (Swerdlow et al. 2008 and 2016) The 
basis of the classification is the normal cell type that most resembles the tumour. 
These subtypes are defined by morphological, phenotypic, molecular, cytogenetic or 
clinical characteristics. Three large groups are incorporated: the B-cell, T-cell, and 
natural killer (NK) cell tumours. The classification also recognizes other less 
common groups. B-cell lymphomas include Hodgkin lymphomas and most non-
Hodgkin lymphomas. They are further divided into indolent (slow-growing) and 
aggressive diseases. Five most common NHLs account for nearly 75% of the 
patients. These are diffuse large cell B-cell lymphoma (DLBCL), follicular 
lymphoma (FL), MALT-lymphoma, mantle cell lymphoma (MCL) and small cell 
lymphocytic lymphoma (SLL), which is known to overlap with chronic lymphocytic 
leukemia (CLL). The remaining lymphomas are much less common. (Swerdlow et 
al. 2008 and 2016, Jaffe et al. 2008, Howlader et al. 2014) 
3.2.1 Epidemiology and aetiology 
The frequency of NHL is increasing. According to the Finnish Cancer Registry, 
NHLs were the seventh most frequent cancer type in women and sixth in men in 
2014. The incidence was, accordingly, 10.3/100 000 and 13.6/100 000. In 2014, 
there were 1338 new cases of NHL in Finland, and 259 cancer deaths due to NHL 
among men and 268 among women. Conversely, the 5-year survival of the NHL 
patients is 65% among men and 64% among women.  (Finnish Cancer Registry 
2014) 
The most common type of lymphoma in the Western countries is DLBCL counting 
for approximately one-third of all adult lymphomas. In Finland, 618 patients were 
diagnosed with DLBCL in 2014 and the incidence was 9.59/100 000 in 2014.  
(Finnish Cancer Registry 2014) European crude incidence of DLBCL is 3–
4/100 000/year. The incidence increases with age from 0.3/100 000/year (35–39 
years) to 26.6/100 000/year (80–84 years). (Tilly et al. 2012). The difference 
between the incidence in Finland and in Europe in general is probably due more to 
strong tradition of cancer registration and uniform cancer care in Finland than in a 
genuine difference in incidence. Similar incidence is also observed in other Nordic 
countries with similar registry traditions. The age structure of the Finnish population 
might also play a role since NHLs are mainly diseases of the elderly.   
For the vast majority of patients the aetiology of DLBCL remains unknown. 
Distinction should be made between cases that are transformed from previous 
indolent lymphomas and cases where there is an actual de novo DLBCL.  
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Immunosuppression caused by AIDS or iatrogenic aetiologies such as 
transplantation or autoimmune disease is known to increase the risk of developing 
the disease. Several chemical substances have been suggested to play a role as 
aetiological agents. These include for example pesticides, hair dyes and fertilizers. 
Diet has also been investigated as a possible risk factor. (Blinder et al. 2008)  Some 
of the alkylating agents used in the treatment of solid tumours have also been 
suspected of predisposing to DLBCL. The combination of alkylating agents and 
ionizing radiation, such as radiation therapy, significantly increases the incidence of 
lymphomas as secondary tumours. A subset of DLBCL, including immunoblastic 
and primary CNS disease is also highly associated with the EBV virus. (Fisher et al. 
2006) Hereditary immunologic deficiency diseases such as ataxia-telangiectasia 
syndrome, Bruton-type gammaglobulinemia, severe combined immunodeficiency 
(SCID), Wiskott–Aldrich syndrome, Duncan syndrome and Chediak–Higashi 
syndrome have also been associated with a higher risk of NHLs. (Hartge et al. 1992, 
Blinder et al. 2008) 
3.2.2 DLBCL subtypes 
DLBCL encompasses a biologically and clinically diverse set of diseases, many of 
which cannot be separated clinically from one another by well-defined and widely 
accepted criteria. This heterogeneity has been appreciated for some time. The WHO 
classification system defines thirteen subtypes, each of which can be differentiated 
based on the location of the tumour, the presence of other cells within the tumour 
(such as T-cells), and whether the patient has certain other illnesses related to 
DLBCL. However, the WHO system does not encompass the more complex 
landscape of the disease, such as the genetic lesions or the tumour 
microenvironment, all of which are now known to have a radical effect on the 
clinical behaviour and prognosis.  These integrated molecular and genetic 
parameters are currently the focus of attention and will be discussed later with more 
detail.  
Therefore, WHO classification does not sufficiently distinguish the diseases with 
different prognosis and cannot therefore be used in the clinic as the basis of 
treatment decisions within the entity of DLBCL. Some of the lesions defined by 
WHO are very rare, and in fact, most DLBCLs are included in the group of DLBCL, 
not otherwise specified (NOS). (Swerdlow et al. 2008, 2016)  
The WHO classification emphasizes the significance of the location and other 
clinical aspects in the diagnosis. It also recognizes the cell-of-origin subtypes, which 
will be discussed in more detail later.  DLBCLs originating from specific 
topographic locations are considered to be their own entities: primary mediastinal 
large B-cell lymphoma (PMBL), primary central nervous system (CNS) DLBCL, 
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and primary cutaneous DLBCL, leg type. Primary CNS DLBCL is indeed managed 
with different treatment regimens than other DLBCLs, but it also has a genomic 
profile that differs from nodal DLBCL. T-cell/histiocyte-rich large B-cell lymphoma 
(THRLBCL) is recognized as a distinct category of DLBCL underscoring the 
importance of the tumour microenvironment. 
Several DLBCL entities characterized by EBV infection are also recognized. 
Lymphomatoid granulomatosis and EBV-positive DLBCL of the elderly are 
extremely rare in western countries. These diseases are mostly caused by a 
weakening in the host immunosurveillance.  
Anaplastic lymphoma kinase (ALK) positive large B-cell lymphoma, plasmablastic 
lymphoma (PBL), the human herpes virus 8-related primary effusion lymphoma and 
large B-cell lymphoma associated with multicentric Castleman disease are rare 
entities. They all have a phenotype resembling terminally differentiated B-cells and 
possess immunoblastic or sometimes plasmablastic features. PBL and human herpes 
virus 8-related lymphomas are mostly diagnosed in patients with immunodeficiency. 
(Swerdlow et al. 2008, Jaffe et al. 2008) 
The classification was recently revised and the new entities regarding DLBCL are 
Epstein-Barr virus positive (EBV+) large cell B-cell lymphomas and EBV+ 
mucocutaneus ulcers. Also, the classification now recognizes high grade B-cell 
lymphomas with rearrangements of MYC and/or BCL6. This subgroup of DLBCL 
has particularly poor prognosis and will be discussed in more detail later. (Swerdlow 
et al. 2016) 
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Table 1. The DLBCL subtypes according to WHO 2008 /2016 Classification: modified from 
Swerdlow et al.2008 and 2016) 
DLBCL, not otherwise specified (NOS)  
            Common morphologic variants Centroblastic 
 Immunoblastic 
 Anaplastic 
            Rare morphologis variants  
            Molecular subgroups Germinal centre B-cell-like (GCB) 
 Activated B-cell-like (ABC) 
            Immunohistochemical subgroups CD5-positive DLBCL 
 Germinal centre B-cell-like (GCB) 
 Non-germinal centre B-cell-like (non-GCB) 
DLBCL subtypes  
            T-cell/histiocyte rich large B-cell lymphoma 
            Primary DLBCL of the central nervous system (CNS) 
            Primary cutaneous DLBCL, leg type 
            EBV-positive DLBCL , NOS 
Other lymphomas of large B-cells  
            Primary mediastinal (thymic) lymphoma 
            Intravascular large B-cell lymphoma 
            DLBCL associated with chronic inflammation 
            Lymphatoid granulomatosis 
            ALK-positive DLBCL  
            Plasmablastic lymphoma  
            Large B-cell lymphoma arising in HHV-8-associated multicentric Castelman disease 
            Primary effusion lymphoma   
            HHV8 positive  DLBCL, NOS 
            EBV+ Mucocutaneus ulcer 
            High grade B-cell lymphoma, with MYC and BCL2and/ or BCL6 rearrangements 
Borderline cases 
             B-cell lymphoma, unclassifiable, features intermediate between DLBCL and BL 
             B-cell lymphoma, unclassifiable, features intermediate between DLBCL and HL 
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3.3 Clinical features of DLBCL 
3.3.1 Symptoms, diagnosis and staging 
DLBCL is an aggressive disease and the patients are almost always symptomatic. 
The first symptom of DLBCL is often a rapidly growing, painless mass that is 
typically an enlarged lymph node in the neck, groin, or abdomen. Patients may also 
experience fever, weight loss and/or drenching night sweats. These are called B-
symptoms. 
In about 40% of DLBCL cases the cancer does not begin in the lymph nodes, but 
instead develops elsewhere. The most common site of extranodal involvement is 
bone marrow. (El-Galaly et al. 2015) About 60% of the patients are diagnosed with 
advanced disease (stage III or IV) and the remaining 40% have localized disease, 
confined to one side of the diaphragm. (Good et al. 2010, Cheson et al. 2014, NCCN 
Guidelines 2015,Tilly et al. 2015) 
The pathological diagnostics of DLBCL include a histological and 
immunohistochemical analysis of the tumour biopsy and a flow cytometric analysis. 
Diagnosis can only be made on the basis of a surgical specimen or an excisional 
lymph node providing enough material for formalin-fixed samples. The volume of 
core biopsy is insufficient for diagnosis and should only be used if emergency 
treatment is needed. The diagnosis should be done by a hematopathologist according 
to the WHO classification. Techniques required for the differential diagnosis are 
immunohistochemistry, flow cytometry, PCR for IgH and TCR gene 
rearrangements, and FISH for major translocations. (Good et al. 2010, Cheson et al. 
2014, NCCN Guidelines 2015, Tilly et al. 2015) Methods used in 
immunophenotypic investigations are listed in Table 2. 
Table 2.  Pathological immunophenotypic diagnostics of DLBCL (Tilly et al 2015) 
Method  
IHC Panel CD20, CD3, CD5, CD10, CD45, BCL2, BCL6, Ki-67, 
IRF4/MUM1, Cyclin D1, kappa/lambda, CD30, CD138, 
EBER-ISH, ALK, HHV8 
Flow cytometry kappa/lambda, CD45, CD3, CD5, CD19, CD10, CD20 
Additional Cytogenetics/FISH: t(14;18), MYC/BCL2 
 
For the diagnosis, the expression of CD20-antigen in the surface of the lymphoma 
cell is essential. DLBCL tumours consist of large CD20-positive cells in which the 
size of the nucleus is at least twice the size of the nucleus in a normal B-cell. The 
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architecture of the tissue is not organized but diffuse. DLBCL is usually a primary 
disease but can also evolve from a more indolent disease, such as follicular, 
marginal zone, lymphoplasmacytic lymphoma or when chronic lymphatic leukaemia 
is transformed. The cell of origin (COO) can be determined using IHC algorithms, 
but at the moment no treatment decisions should be based on it. (Good et al. 2010, 
Cheson et al. 2014, NCCN Guidelines 2015,Tilly et al. 2015) 
A clinician should perform a thorough clinical examination and clarify the medical 
history, together with laboratory investigations. FDG-PET/ CT scan is currently 
recommended as the gold standard for staging DLBCL patients (Tilly et al. 2015). 
PET/CT is more accurate than contrast-enhanced CT with increased sensitivity for 
nodal and extranodal sites (Cheson et al. 2014, Barrington et al. 2014). Laboratory 
tests should include complete blood count, liver and kidney function tests, HIV, 
hepatitis serology, LDH and urate. Bone marrow biopsy, MR scan for lymphoma of 
head and neck and lumbar puncture can be made if the clinical situation requires. All 
of these measures are essential for the diagnosis and risk determination of DLBCL. 
The staging is done according to Ann Arbor (Table 3) and risk group is determined 
by International Prognostic Index (IPI). IPI consists of five clinical factors and it 
provides each patient a risk group thus helping clinical decision making. IPI will be 
discussed with more detail in Chapter 3.4.1. (Good et al. 2010, Cheson et al. 2014, 
NCCN Guidelines 2015,Tilly et al. 2015) 
Table 3 Ann Arbor Lymphoma Staging 
Ann Arbor Stage 
Stage I Disease in single lymph node or lymph node region. 
Stage II Disease in two or more lymph node regions on same side of 
diaphragm. 
Stage III Disease in lymph node regions on both sides of the diaphragm   
Additional A  Asymptomatic 
B  Presence of B symptoms (fever, night sweats and weight loss) 
X  Bulky nodal disease 
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3.3.2 Treatment 
3.3.2.1 Chemotherapy 
Systemic combination chemotherapy is the basis of DLBCL treatment. The 
development of anthracycline-based combination treatment regimen in the early 
1970s marked the dawn for a possibility of cure for a DLBCL patient. The addition 
of doxorubicin to cyclophosphamide, vincristine and prednisone (CHOP) resulted 
the new golden standard for the treatment with about half of the patients cured. 
(Gordon et al. 1992, Cooper et al. 1994, Fisher et al. 1994) Subsequently, the 
addition of other chemotherapy agents to CHOP, intensifying the dose, or more 
complex regimens failed to improve outcomes for decades. (Fisher et al. 2006, 
Olivieri et al. 2005, Gaynor et al. 2001) Moreover, CHOP has proved to be less toxic 
than more complex and dose dense therapies. It is also associated with less cost. 
Nonetheless, long-term remissions were achieved in only about 45% of patients with 
combination chemotherapy. With emerging evidence of the heterogeneity of the 
disease, it has now been shown that certain subgroups of patients might benefit from 
more complex chemotherapy regimens.  
3.3.3 Anti-CD20-therapies 
Rituximab is a chimeric (mouse and human) IgG1 recombinant humanized 
monoclonal antibody targeting the CD20 antigen. CD20 is a cell surface antigen that 
is expressed on the surface of most normal and malignant B-cells through the 
maturation of B-cells from pre-stage to mature antibody-secreting plasma cells. It is 
only absent on terminally differentiated plasma cells. It is therefore expressed by the 
majority of B-cell malignancies. Rituximab annihilates B-cells and is therefore used 
in the treatment of not only B-cell lymphomas but also other diseases characterized 
by an excessive number of B-cells or overactive and dysfunctional B-cells. (Feugier 
2014) 
The function of CD20 remains unknown and it has no known ligand. It is speculated 
that CD20 plays a role in Ca2+ influx across plasma membranes, maintaining 
intracellular Ca2+ concentration and thus allowing the activation of B-cells. 
(Feugier 2014, Abulayha et al. 2014) 
Rituximab binds to CD20 and forms a cap to the side of B-cells where CD20 is 
found. The presence of this cap is shown to attract the natural killer cells in 
destroying the B-cells. When a NK cell is locked in to this cap it has an 80% success 
rate at killing the cell (in vitro). (Feugier 2014, Abulayha et al. 2014) 
All mechanisms of action of rituximab are not yet fully understood but include at 
least antibody-dependent cell-mediated cytotoxicity (ADCC), complement-mediated 
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lysis (CDC) and direct induction of apoptosis. ADCC depends on immune cells, 
natural killer cells, T-cells, and macrophages recognizing and killing antibody-
labelled target cells. This leads to cell lysis. In CDC, cell lysis is caused by 
complement proteins recruited by antibody inducing holes in the cell membrane. 
This leads to flooding the cell and hence cell death. Binding of rituximab to cell 
surface also signals the cell to self-destruct: apoptosis. (Feugier 2014, Abulayha et 
al. 2014) 
Rituximab was approved by the US Food and Drug administration (FDA) in 1997 to 
treat B-cell NHLs resistant to other chemotherapy regimens. This was based on its 
safety and effectiveness in clinical trials. First indication was low-grade B-cell 
lymphomas. After that, several trials started combining rituximab with CHOP (R-
CHOP) for DLBCL. In contrast with prior attempts to intensify CHOP, rituximab-
related toxicities were not overlapping with those of CHOP. 
Rituximab is on the WHO's list of essential medicines, a list of the most important 
medications needed in a basic health system. 
Nowadays, rituximab is also available in subcutaneous form and it has proven to be 
non-inferior to intravenous rituximab in FL (Davies et. al 2014). A randomized 
phase III study evaluating the efficacy and safety of subcutaneous versus 
intravenous rituximab in combination with CHOP in patients with DLBCL is 
ongoing. In addition, new generation CD20 antibodies ofatumumab and 
obinutuzumab are currently being tested in clinical trials in combination with 
chemotherapy. Ofatumumab is a human anti-CD20 monoclonal antibody that targets 
a different epitope than rituximab and it has demonstrated activity in rituximab-
refractory indolent lymphomas (Czuczman et al. 2012) but has failed to show 
superiority over rituximab in DLBCL (Van Imhoff et al. 2014). Obinutuzumab's 
mechanism of action differs from rituximab in enhanced ADCC (Mössner et al. 
2012). 
3.3.4 Immunochemotherapy 
Today, rituximab is used in combination with chemotherapy in DLBCL. This R-
CHOP regimen is considered as standard of care. In pivotal DLBCL trials in early 
2000s, previously untreated patients were randomized to treatment with up to 8 
cycles of an anthracycline-based chemotherapy regimen, with or without rituximab 
(Table 4).  The Groupe d’Etude de Lymphome d’Adultes (GELA) was the first to 
publish a randomized controlled trial demonstrating the benefit of adding rituximab 
to CHOP chemotherapy (R-CHOP). This GELA LNH 98-5 trial was designed for 
the treatment of elderly patients (age over 60 years) with de novo DLBCL. R-CHOP 
improved median event-free survival versus CHOP alone. 5-year and 10-year 
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updates demonstrated that the benefit was maintained over time, indicating an 
improvement in the cure rate for this patient population. (Feugier et al. 2005, 
Coiffier et al. 2002, 2010)  Subsequently, American Intergroup ECOG 4494 trial 
confirmed the results and demonstrated that R-maintenance therapy does not add 
benefit after R-CHOP (Habermann et al. 2006). The German High-Grade Non-
Hodgkin Lymphoma Study Group (DSHNHL) RICOVER-60 trial also 
demonstrated the superiority of immunochemotherapy over chemotherapy in elderly 
patients with DLBCL. Hence, RICOVER trial also demonstrated that six cycles of 
chemo was not inferior to eight cycles. (Pfreundschuh et al. 2006) Further, 
DSHNHL MINT trial confirmed the efficacy of immunochemotherapy in young 
patients (age 18–60 years) with a favourable prognostic profile. UK NCRI and 
GELA LNH03-6B trials validated that R-CHOP administered on three week cycles 
is not inferior to R-CHOP administered biweekly. (Cunningham et al. 2013, Delarue 
et al. 2013) The updates of these trials have further validated the results. The trials 
and the results are listed in Table 4. 
Table 4. Pivotal DLBCL immunochemotherapy trials 
Trial Treatment Patients Results Lead author 
GELA LNH 
98-5 
R-CHOP vs 
CHOP 
>60y   
n=399 
 
5-y EFS 29% vs 47% 
5-y PFS 54% vs 30% 
5-y OS 58% vs 45% 
Coiffier 2002, 
2010 
Feugier 
2005(update) 
ECOG 4494 R-CHOP vs 
CHOP ± 
maintenance R 
>60y   
n=632 
3-y FFS 53% vs 46% Habermann 
2006 
DSHNHL 
RICOVER-60 
R-CHOP14x6 vs 
R-CHOP14 x8 
vs CHOPx6 vs 
CHOP x 8 
>60y 
n=1222 
3-y EFS 67% vs 63% vs 
47% vs 53% 
Pfreundschuh 
2008 
DSHNHL  
MINT 
R-chemo vs 
chemo 
18-60y 
n=823 
6-y EFS 74% vs 56% 
3-y OS 79% vs 59% 
Pfreundschuh 
2006 
UK NCRI R-CHOP 14 vs 
R-CHOP21 
≥ 18y 2-y OS 83% vs 81% Cunningham 
2013  
GELA 
LNH03-6B 
R-CHOP14 vs 
R-CHOP21 
60-80y 
n=602 
3-y EFS 56% vs 60% Delarue 2013 
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Based on these pivotal trials, immunochemotherapy is standard of care in the 
treatment of DLBCL patients. It is administered according to risk stratification, 6–8 
cycles every three weeks. The treatment regimen is chosen bearing in mind the 
individual characteristics and the IPI score of the patient. Treatment regimens 
according to ESMO and NCCN guidelines are represented in Table 5. Young high 
risk patients may benefit from the addition of etoposide and administration 
biweekly. Conventional R-CHOP regimen is sometimes too toxic for the elderly or 
co-morbid patients. Elderly patients (≥80y) are known to better tolerate the R-mini-
CHOP-regimen where the dosage of the chemotherapy agents is lower (Peyrade et 
al. 2011). Multi-professional teamwork is recommended in the clinical evaluation 
and treatment choices, and clinical trials should be prioritized. (Tilly et al. 2015, 
Pfreundschuh et al. 2006, Cunningham et al. 2013, Feugier et al. 2005) 
Table 5. Treatment recommendations in DLBCL, modified from Tilly et al. 2015 
DLBCL patients ≤60 years   
IPI low risk, no bulk 
 
 
IPI low risk with bulk 
IPI low-intermediate risk 
IPI intermediate-high risk 
IPI high risk 
R-CHOP21 x 6 R-CHOP21 x6 + IF-RT R-CHOP21 x6-8 
R-CHOP14 x6 + Rx8 
R-CHOEP14 x6 
CNS prophylaxis consideration in patients at risk for CNS progression 
 
Elderly DLBCL patients >60 years 
Fit, 60-80 years 
 
>80 years without cardiac 
dysfunction 
Unfit or frail or >60 years 
with cardiac dysfunction 
R-CHOP21 x 6-8 
 
Attenuated regimens 
R-miniCHOP21 x6 
Gemcitabine, etoposide or 
liposomal doxorubicin 
instead of doxorubicin 
R-C(X)OP21 x6 
or palliative care 
CNS prophylaxis consideration in patients at risk for CNS progression 
 
3.3.5 CNS Prophylaxis 
The incidence of central nervous system (CNS) relapse in patients with DLBCL has 
been reported to be between 1–10%. CNS relapse is very often fatal. Patients at 
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greatest risk of CNS recurrence include those with advanced stage, elevated LDH 
and extranodal involvement, such as testes or bone marrow, paranasal sinuses, 
epidural or orbit. Most of the CNS recurrences are diagnosed early on, either during 
the initial treatment or shortly after. The question of CNS prophylaxis remains 
controversial since there is no randomized evidence of the benefits or optimal 
dosage of the prophylaxis. (Ghose et al. 2014) The efficacy of rituximab in 
preventing CNS relapses has also been controversial. A recent analysis of seven 
prospective studies concluded that there was no statistically significant difference in 
CNS relapses between patients treated with or without rituximab (Ghose et al. 
2015). Chemotherapeutic agents able to penetrate to the CNS have the most promise 
in preventing CNS relapse. They can be administered intravenously or intrathecally. 
The most commonly used agent is methotrexate. (Ghose et al. 2015) The efficacy 
and safety of early CNS prophylaxis was also studied in Nordic Lymphoma Group´s 
NLG-LBC-04 trial, where 156 high risk patients received systemic CNS prophylaxis 
prior to R-CHOEP treatment. CNS relapse rate was lower than expected, since only 
seven patients experienced CNS relapse, suggesting that CNS relapse may be 
reduced by earlier prophylaxis. (Holte et al. 2013) Early CNS prophylaxis is further 
studied in the ongoing NLG-LBC-05 trial (Leppä et al. 2013). 
Primary CNS lymphoma (PCNSL) is rare and thought to be its own entity. It is 
recommended to be treated with high dose methotrexate (MTX) based regimens or 
radiotherapy. MTX combined with AraC is proven to be more efficient than single-
MTX. (Pels et al. 2003, Ferreri et al. 2009) 
3.3.6 Radiotherapy 
Consolidation by radiotherapy (RT) as a part of the first-line treatment in DLBCL 
remains under debate. In the pre-rituximab era, involved field RT (IF-RT) was 
indicated as consolidation therapy of bulky lesions or post-chemotherapy residual 
tumours. 40 to 50 Gy IF-RT was also standard of care as combined with three 
courses of chemotherapy for patients with a limited stage disease. (Miller et al. 1998 
and 2001)  
In a disease where the cure rate is high, the sequalae caused by radiation, such as 
secondary malignancies and cardiac disease, have also raised concern. Lower doses 
of radiation may reduce the risk of these side effects. 
In the rituximab era, R-CHOP × 6 with radiotherapy to the sites of previous bulky 
disease was shown to be effective in the group of young low-intermediate risk 
patients with a bulky disease, based on the results of the MINT study. (Pfreundschuh 
et al. 2011) In the young high-risk group of patients, the role of consolidation by RT 
to initial sites of bulky disease is unknown. The role of interim PET to select 
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patients who could benefit from RT is under evaluation (Sehn et al. 2014). A 
prospective evaluation of RICOVER-60 trial suggested that additive RT to bulky 
sites abrogates bulky disease as a risk factor and improves the outcome of elderly 
patients. (Held et al. 2014)  Reduced dose RT, 30 Gy in aggressive NHLs, has been 
proven to be efficient in a phase III randomized trial (Lowry et al. 2011). The role of 
RT after CR to immunochemotherapy remains under debate. A recent meta-analysis 
suggested that it could improve outcomes but prospective trials are needed. (Hu et 
al. 2015, Hodgson et al. 2015)  
3.3.7 Treatment after relapse 
In about 10–15% of the cases, DLBCL is resistant to the first-line treatment, and 
about 20–40% patients have a relapse after first responding to treatment. Usually, 
the relapses are seen within three years of the initial treatment. (Sweetenham 2005) 
If a patient experiences a relapse after first-line R-CHOP-treatment, the prognosis is 
often poor, especially if the disease does not response to first line treatment. 
Relapses are often chemosensitive but the duration of the second complete or partial 
response to treatment is frequently shorter than a year. Clinical features, such as 
poor performance status, elevated LDH and disseminated disease predict poor 
outcome to second-line treatment. (Moskowitz 2006)  In patients experiencing 
relapse more than 12 months after diagnosis, prior rituximab treatment does not 
affect EFS (Gisselbrecht et al. 2010). 
The most common salvage chemotherapeutic regimens at relapse include ICE 
(ifosfamide, etoposide, carboplatin), GEMOX (gemcitabine, oxaliplatin), DHAP 
(dexamethasone, high-dose cytarabine, cisplatin) and MINE (mesna, ifosfamide, 
mitoxantrone, etoposide). (Tilly et al. 2015) Patients with good physical condition 
and chemoresponsive disease after salvage therapy should be considered for high-
dose chemotherapy supported by autologous stem cell transplant (HDT-ASCT). 
(Philip et al. 1995) If the disease is responsive to second-line chemotherapy HDT-
ASCT, cure can be achieved in approximately 50% to 60% of cases. (Sweetenham et 
al. 2005, Gisselbrecht et al. 2010) The patients not eligible to ASCT can be treated 
with the combination chemotherapy previously mentioned or the R-GEMOX (rituxi-
mab, gemcitabine, oxaliplatin) or R-MINE (rituximab, mesna, ifosfamide, 
mitoxantrone, etoposide) regimens. Chemotherapy can be accompanied with local 
radiation therapy. (Friedberg et al. 2011, Tilly et al. 2015) 
Patients with early relapses after rituximab-containing first-line therapy have a poor 
prognosis, with no difference between the effects of R-ICE and R-DHAP 
(Gisselbrecht et al. 2010). Allogeneic transplant can be considered in special 
circumstances, for example if the mobilization of the stem cells is not successful or 
 22 
 
 
in rare cases if there is a disease relapse after ASCT. (van Kampen et al. 2011) 
These are the patients that would benefit from individual therapy first-line if the 
biological factors behind the poor prognosis would be better identified at the time of 
the diagnosis. If possible, these patients should be treated in clinical trials testing 
novel regimens. (Tilly et al. 2015) 
3.3.8 Novel therapies 
DLBCL is a heterogeneous disease both clinically and biologically. The 
heterogeneity is not as yet emphasized in daily clinical practice as the treatment 
remains the same R-CHOP for most of the patients. Advances in genomics and 
cancer biology have produced a vast body of knowledge regarding the molecular 
pathogenesis of lymphoma. Instead of a single uniform disease, DLBCL is now 
regarded as bundle of molecularly heterogeneous diseases, each arising from distinct 
oncogenic mechanisms. In conjunction with the advances in lymphoma biology and 
cancer biology in general, several new classes of molecularly targeted agents have 
been developed. Before, the development of new drugs for treating lymphoma was 
mostly empiric with limited knowledge of the molecular target and its involvement 
in the diseases. The mechanisms of traditional chemotherapy agents are nonspecific 
and the therapeutic It can be speculated that the variability in clinical responses is 
likely to result from underlying molecular heterogeneity. 
In the era of personalized medicine, the challenge for the treatment of patients with 
lymphoma will involve correctly matching a molecularly targeted therapy to the 
unique genetic and molecular composition of each individual lymphoma. Many new 
agents and treatment regimens are currently being tested in clinical trials for patients 
with newly diagnosed or relapsed and refractory DLBCL. There are a number of 
promising targeted agents in relapsed and refractory DLBCL. These agents can be 
combined with front line chemotherapy. Also, as mentioned above, next generation 
CD20 antibodies are undergoing clinical trials. Novel agents such as lenalidomide, 
ibrutinib, bortezomib, CC-122, epratuzumab or pidilizumab used as a single-agent or 
in combination with immunochemotherapy have already demonstrated promising 
activity in patients with relapsed and refractory DLBCL. (Roschewski et al. 2014, 
Camicia et al. 2015)  
Potential approach to target refractory DLBCL are chimeric antigen receptor-
modified autologous T-cells (CAR T-cells) targeted specifically to antigens 
expressed by B-cell malignancies. T-cells that are genetically modified to express 
chimeric antigen receptors (CARs) recognizing the B-cell-associated CD19 or CD20 
molecules. T-cells expressing anti-CD19 CARs are activated by CD19 and 
recognize and kill CD19+ primary malignant B-cells. The CAR T-cell based 
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immunotherapy approach serves as an example of adoptive T-cell immunotherapy 
and appears to be safe and feasible. (Kochenderfer et al. 2013 & 2015) 
BCL2 overexpression and double hit lymphomas are discussed with more detail 
later. BCL2 inhibition is also showing promise in relapsed DLBCL. For example, 
Venetoclax is currently in early phase clinical trials in patients with relapsed or 
refractory NHL including DLBCL and the premilinary results have been promising. 
(Davids et al. 2014) 
Better understanding of immunology and antitumor immune responses in cancer has 
prompted the development of novel immunotherapy agents like PD-1 checkpoint 
inhibitors. These novel agents, for example nivolumab, are also investigated in 
lymphoma (Lesokhin et al. 2016)  
Some new possible treatments and their targets are listed in Figure 2. 
 
Figure 2 Potential new agents and their targets in DLBCL (modified Riihijärvi et al. 2014) 
3.4 Clinical prognostic factors 
Prognostic models are used for risk stratification of a single patient and can roughly 
be divided into clinical and biological prognostic factors. Clinical risk factors are 
used for risk stratification whereas biological prognostic factors have potential to be 
used as a tool for treatment decisions on targeted therapies in the near future. 
Clinical prognostic factors in DLBCL can be divided into those related primarily to 
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the host, to the tumour and its aggressiveness, and to the factors related to the 
treatment strategy. (Narayanan et al. 2010) 
3.4.1 International Prognostic Index IPI 
In the 1970s and 1980s, the primary prognostic tool in assessing the treatment 
outcome in newly diagnosed DLBCL was the Ann Arbor classification described 
above in Table 3. Ann Arbor staging was originally developed for Hodgkin 
lymphoma (HL) emphasizing the distribution of nodal disease sites. HL commonly 
spreads through contiguous groups of lymph nodes and radiotherapy has an 
important role in therapy. Therefore, accurate knowledge of the stage was essential. 
The patterns of disease spread in NHL differ from HL and therefore the Ann Arbor 
classification system was found less accurate in identifying prognostic subgroups of 
patients with aggressive NHL. The stage of the disease does not consistently 
distinguish between patients with different long-term prognoses. 
The International Prognostic Index (IPI) project was undertaken to develop a model 
for predicting outcome in patients with aggressive non-Hodgkin's lymphoma on the 
basis of the patients' clinical characteristics before treatment. A retrospective 
analysis published in 1993 was performed by the International Non-Hodgkin 
Lymphoma Prognostic Factor Project on 2031 patients with aggressive NHL, treated 
with a doxorubicin-based chemotherapy regimen such as CHOP between 1982 and 
1987. Several patient characteristics were collected and analysed to determine 
whether they were associated with differences in survival. The factors that emerged 
as significant in univariate analysis were Ann Arbor stage, age, elevated serum 
lactate dehydrogenase (LDH), performance status, and the number of extranodal 
sites of disease. These five features were used to design a model to predict an 
individual patient's risk of death. When the patients were divided in to risk groups 
according the IPI points, four groups emerged. Risk factors and according risk 
groups are presented in Table 6 (IPI-Project, 1993). 
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Table 6. International Prognostic Index. Modified from IPI-project 1993. 
International Prognostic Index 
One point is assigned for each  of 
the  risk factors: 
The sum of the points  correlates with the following 
risk groups: 
Age greater than 60 years 
Stage III or IV disease 
Elevated serum LDH 
ECOG performance status of 2–4 
More than 1 extranodal site 
Low risk (0-1 points) – 5-y survival  73% 
Low-intermediate risk (2 points) – 5-y survival 51% 
High-intermediate risk (3 points) – 5-y survival  43% 
High risk (4-5 points) – 5-y survival 26% 
  
A simplified index, age-adjusted IPI, aa-IPI was also validated by IPI Project and 
can be used when comparing patients within an age group (i.e. 60 or younger, or 
over 60). It includes only three of the above factors: stage, LDH-level and ECOG 
performance status. Again, the sum of the points allotted correlates with the 
following 5-year survival risk groups: Low risk (0 points) – 83% 5-y survival, Low-
intermediate risk (1 point) –- 69%, High-intermediate risk (2 points) – 46% and 
High risk (3 points) – 32%, respectively. 
The IPI risk stratification remains an important clinical tool in everyday oncology 
practice. It was developed and validated prior to the use of rituximab. As discussed 
above, immunochemotherapy has dramatically improved the outcomes of lymphoma 
patients since and this made it imperative to re-evaluate the IPI-index in the 
immunochemotherapy era. This was done by Ziepert at al. in a study involving 1062 
DLBCL patients treated with immunochemotherapy. The patients were included in 
three prospective clinical trials. The multivariate proportional hazards analysis 
affirmed the prognostic relevance of IPI score for PFS, EFS and OS. (Ziepert at al. 
2010) Before this, Sehn et al. had proposed the R-IPI model of two risk groups 
based on the results in a smaller retrospective analysis on 365 DLBCL patients 
treated with immunochemotherapy (Sehn et al. 2007). 
Helsinki University Central Hospital Cancer Center treatment results categorized 
according to the IPI classification are shown in Figure 3. The results are in line with 
the published data discussed before. 
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Figure 3. HUCH DLBCL Patients, treatment results according to IPI score. (modified 
Riihijärvi et al. 2014) 
3.4.2 Other clinical prognostic factors 
3.4.2.1 Gender 
In patients treated with immunochemotherapy the male gender is a poor prognosis 
factor (Riihijärvi et al. 2011, Carella et al. 2013, Pfreundschuh et al. 2014a) (Figure 
4) Predictive effect of sex is most obvious in the elderly patients over 60 years of 
age, and the result of a slower metabolism and clearance of rituximab in women 
compared to men (Pfreundschuh et al. 2014a). Also, the weight of the patient has an 
influence to the clearance of rituximab.  Optimal dosing and method of 
administration of rituximab was investigated in the German Lymphoma Group trials. 
(Pfreundschuh et al. 2014b) 
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Figure 4. PFS according to female and male genders. (modified Riihijärvi et al. 2011) 
3.4.2.2 Bulk tumours 
Large bulk tumours (over 10 cm) are known to be an adverse prognostic factor. 
Involved field radiotherapy is known to improve the outcome and obliterates the 
negative prognostic value of a bulk tumour (Pfreundschuh et al. 2008).  
3.4.2.3 Treatment response 
Response rate after the primary treatment is highly predictive of outcome. PET/CT 
imaging has proved to be highly sensitive in determining sites of disease in DLBCL. 
A positive PET/CT scan at the end of treatment is highly predictive for residual or 
recurrent disease, and is associated with an inferior PFS and OS (Martelli et al. 
2014). Also PET-positivity after two treatment cycles is highly prognostic but high 
number of false positive scans in the trials requires a new biopsy as verification. The 
role of the PET/CT scan during therapy is controversial. Although early 
retrospective studies suggested a difference in outcome based on the results of an 
interval PET scan, subsequent prospective studies have not supported these findings 
and there isn’t subsequent evidence that a change in the treatment strategy would 
benefit the patient. (Cheson et al. 2014, Tilly et al. 2015) 
3.4.2.4 Duration of the remission 
One of the strongest predictors of long-term survival for a DLBCL patient is the 
duration of the remission until a minimum of 24 months after initial diagnosis. Most 
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relapses occur within the first 12–24 months after diagnosis and patients with 
relapsed or recurrent disease carry a significantly inferior prognosis despite salvage 
chemotherapy and ASCT. On the other hand, patients who are event-free at 24 
months after diagnosis have an excellent prognosis with an OS similar to that of an 
age- and sex- matched general population.  (Maurer et al. 2014, Tilly et al. 2003) 
3.4.2.5 Lymphocyte count 
There is increasing evidence that tumour microenvironment and host immunity play 
an important role in lymphoma progression (Lenz et al. 2008a). This will be 
discussed in more detail later. The absolute lymphocyte count (ALC) calculated 
from the complete blood count is considered a surrogate for host immunity. Multiple 
retrospective studies have assessed the role of ALC at diagnosis in predicting 
outcomes of DLBCL (Chae et al. 2012, Cox et al. 2008, Kim et al. 2007, Li et al. 
2007). Although various ALC cutoffs have been used, most studies report that a 
higher ALC at the time of diagnosis is associated with improved survival. These 
findings seem to hold true for both the pre- and postrituximab era (Oki et al. 2008, 
Porrata et al. 2010 & 2012). Attempts have been made to devise a new prognostic 
scoring system that incorporates the ALC at diagnosis with the IPI. (Cox et al. 2008)  
In contrast to a high ALC being associated with a good prognosis, high levels of 
blood monocytes are associated with poor prognosis. (Wilcox et al. 2011, Cox et al. 
2008)  
The optimal method of incorporating the ALC data into our existing scoring system, 
either with an absolute cutoff value for ALC or with L/M ratio, has not been 
validated prospectively. The ALC may also have significance during routine 
surveillance after the completion of immunochemotherapy.  
Systemic immune suppression in NHL has also been suggested to result from altered 
monocyte phenotype in peripheral blood (Lin et al. 2011). The presence of 
immunosuppressive monocytes is associated with a more aggressive disease and 
faster rate of progression. (Lin et al. 2011). 
3.5 Biology of DLBCL 
3.5.1 Cell of origin 
Over the past few decades gene expression profiling (GEP) has revealed the 
molecular heterogeneity of DLBCL. Based on these results DLBCL can be 
classified into different molecular subsets. In fact, DLBCL has more biological 
diversity than other lymphomas. In the pivotal studies Alizadeh et al. (2000) and 
Rosenwald et al. (2002) used microarray gene expression profiling (GEP) in 
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dividing DLBCL into subgroups. GEP is a method that can be used to identify the 
expression of genes throughout the genome at the same time, the scale and form a 
tumour sample RNA expression profile. Three different groups were found 
reflecting the cell of origin (COO), i.e. the lymphocyte differentiation stage where 
the malignant cell is born. These subgroups have different pathologies, specific 
genetic alterations, molecular signalling pathways, and treatment outcomes. All 
DLBCLs are derived from mature B-cells that have undergone the germinal centre 
reaction. Germinal centre B-cell-like (GCB)-DLBCL -subtype exhibits a 
transcriptional profile that resembles that of GC B-cells. Activated B-cell-like 
(ABC)-DLBCL resembles post-germinal B-cells entering the plasmablastic 
differentiation. The third completely separate entity revealed inside the DLCBL is 
the primary mediastinal B-Cell lymphoma, PMBL. PMBL may arise from thymic B-
cells and it is thought to be closer to Hodgkin lymphoma both genetically and in its 
clinical behaviour. Additionally, there is a small group of DLBCLs that cannot be 
precisely classified into these entities. (Pasqualucci et al. 2014, Rui et al. 2011, 
Alizadeh et al. 2000, Rosenwald et al. 2002) 
Currently, GEP technology is not available in clinical practice, although a number of 
assays suitable for everyday practice are being developed (Scott 2015). DLBCL can 
also be divided into germinal centre and non-germinal centre lymphomas using IHC-
based classifications. The most commonly used is Hans algorithm which applies 
CD10-, BCL6- and MUM1-stainings in classifying the tumours into two categories: 
germinal-centre and non-germinal centre lymphomas. (Hans et al. 2004) Since Hans, 
a number of other IHC-based algorithms have been described (Choi et al. 2009, 
Meyer et al. 2010, Visco et al. 2012, Nyman et al. 2009, Muris et al. 2006).  The 
accuracy of immunohistochemical algorithms is not thought to be equivalent to 
GEP-level analysis. (Scott 2015)  
3.5.2 Genetic landscape 
Genome-wide sequencing technologies have revolutionized the understanding of the 
genetic basis of DLBCL. Over 300 genetic alterations associated with DLBCL have 
been found. Some of these mutations are distinct to one of the COO subtypes and 
others overlap between the subtypes highlighting the heterogeneity and diversity of 
the disease. The coding genome of DLBCL appears to have a higher degree of 
complexity when compared to other B-cell malignancies. (Pasqualucci et al. 2015 
and 2014, Camicia et al. 2015, Morin et al. 2013, Testoni et al. 2015) The most 
common genetic lesions are listed below in Figure 5. 
Among the most common genetic lesions in DLBCL are mutations and deletions 
affecting acetyl-transferase- and methyltransferase-enzymes. These enzymes have 
pivotal roles as epigenetic modifiers and their loss of function may favour tumour 
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development. These mutations are shared across COO subtypes. For instance, 
inactivating mutations in CREBBP and EP300 can lead to deregulation of the 
BCL6-p53 axis. These mutations have been detectable in up to 35% of DLBCL. 
Mutations lead to constitutive action of oncoprotein BCL6 and decrease tumour 
suppressor p53 function. (Bereshchenko  et al. 2005, Pasqualucci et al. 2011, &  
2015) Histone methyltransferase encoding MLL2 (mixed-lineage leukaemia 2) is the 
most common target for mutations in B-cell lymphomas and it can be found in 
almost 90% of FL but also in 30% of DLBCL. Lysine-4 position of Histone 3 
(H3K4) encoded by MLL2 is thought to have a tumour suppressor role. Oncogene 
EZH2 also encodes for a histone methyltransferase that represses gene expression by 
trimethylating H3K27. EZH2 gain-of-function mutations are found in 22% of GCB 
DLBCL and may represent a promising new therapeutic target. In summary, 
alterations in these chromatin remodelling genes may impose significant effects on 
transcriptional regulation and contribute to lymphomagenesis by epigenetically 
reprogramming the lymphoma cell. (Morin et al. 2011, Pasqualucci et al. 2015) 
Another type of genetic lesions commonly found in DLBCL involves pathways 
leading to immune escape phenotype. Mutations in the genes encoding beta2-
microglobulin (B2M) lead to loss of surface B2M, which can help lymphoma cells 
to escape cytotoxic T lymphocytes. (Challa-Malladi et al. 2011) Mutations in CD58 
can also protect the lymphoma cells from both CTL- and natural killer cell -
mediated lysis. 
Mutations in transactivator gene CIITA and immunomodulatory proteins PDL1 and 
PDL2 can also lead to reduced tumour cell immunogenicity and impaired anti-
tumour responses. These lesions are preferentially observed in PMBCL (Pasqualucci 
et al. 2014, Steidl et al. 2011) 
Finally, mutations leading to constitutive activation of NF-kappaB pathway in ABC-
DLBCL have been widely studied. These genetic alterations include CD79A/B 
mutations leading to chronic activity of BCR signalling, oncogenic toll-like receptor 
MYD88 mutations and alterations in negative and positive regulators of NF-kB. 
These same signals can also trigger other downstream signalling cascades, including 
for example PI3K and ERK/MAP. In normal lymphocytes these pathways are active 
only short periods of time. Chronic activation of BCR signalling pathway can also 
affect downstream on Syk, BTK, PKCbeta activities. Ultimately, continuous activity 
of NF-kappa B signalling pathway maintains rapid proliferation of cancer cells and 
prevents cell death. (Pasqualucci et al. 2014 and 2015) 
In summary, GCB tumours express genes associated to germinal centre reaction 
such as CD10, LRMP, LMO2 and BCL6. Approximately 40% of GC tumours 
harbour t(14;18) translocation, 15–30% REL amplification and 22% mutations in 
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EZH2. Respectively, ABC tumours  are characterized by expression of genes 
associated with plasma cell differentiation,   such as IRF4, PIM2 and FOXP1 and 
constitutive activation of NF-kappa B signalling pathway leading to chronic 
activation of BCR via mutations in CARD11 and CD79A / B genes . (Pasqualuzzi et 
al. 2014, 2015, Rui et al. 2011, Testoni et al. 2015) 
 
Figure 5 The Most common genetic lesions in DLBCL (modified Riihijärvi et al. 2014) 
3.5.3 Tumour microenvironment 
Cancer cells are defined by an autonomous capacity to undergo uncontrolled 
proliferation and survival through the activation of oncogenes and inactivation of 
tumour suppressor genes. Nevertheless, a cancer cell does not survive alone and the 
formation of a clinically relevant tumour requires support from the surrounding non-
neoplastic stroma, also referred to as the tumour microenvironment.  
The tumour tissue contains a variety of other cells and structures and the tumour 
cells depend upon the signals of their environment. This tumour microenvironment 
(TME) includes for example the surrounding blood vessels, immune cells, 
fibroblasts, bone marrow-derived inflammatory cells, lymphocytes, signalling 
molecules and the extracellular matrix. The tumour and the surrounding 
microenvironment interact constantly. Cancer cells can influence the 
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microenvironment by creating extracellular signals, thus promoting angiogenesis 
and inducing peripheral immune tolerance, while the immune cells in the 
microenvironment can affect the growth and evolution of cancerous cells. TME also 
contributes to tumour heterogeneity within a certain cancer type. (Lorusso et al. 
2008, Quail et al. 2013) 
There is increasing evidence that TME and host immunity play an important role 
also in the progression of lymphoma. Besides the COO, another notable finding of 
recent GEP studies is the importance of the tumour microenvironment, i.e. the cells 
and microscopic structures interspersed between the malignant cells within the 
tumour. (Lenz et al. 2008a) 
Based on GEP studies Lenz et al. (2008a) generated a survival model that includes 
two gene-expression signatures in regard of TME, stromal-1 and stromal-2.  These 
gene signature profiles reflect the character of the non-malignant cells in the 
DLBCL tumour.  
The stromal-1 signature includes extracellular matrix encoding genes that are mainly 
expressed in many normal mesenchymal tissues. Another characteristic feature of 
stromal-1 type tumours is the infiltration by cells of the myeloid lineage. These 
include for example tumour-associated macrophages, myeloid-derived suppressor 
cells, and Tie2-expressing monocytes. These cells are known to suppress T-cell 
immune responses and initiate angiogenesis. 
The stromal-2 signature, on the other hand, is said to be an “angiogenic switch” in 
which the progression of a hyperplastic lesion to a fully malignant tumour is 
accompanied by new blood-vessel formation. Stromal-2 signature DLBCLs are 
associated with increased tumour blood-vessel density and also a poorer survival 
after therapy. The presence of gene expression signatures commonly associated 
with macrophages, T-cells, and remodelling of the matrix has been shown to have 
prognostic significance.  Also, expression of genes coding for pro-angiogenic factors 
is correlated with poorer survival. (Lenz et al. 2008a) 
3.5.4 Angiogenesis 
The process where new blood vessels form from pre-existing vessels is called 
angiogenesis. The first vessels in the developing embryo form through 
vasculogenesis, after which angiogenesis is responsible for most, if not all, blood 
vessel growth during development and in disease. Angiogenesis is a normal and vital 
process in growth and development, as well as in wound healing and in the 
formation of granulation tissue. However, as discussed above, it is also a hallmark of 
cancer, a fundamental step in the transition of tumours from a benign state to a 
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malignant one. Independent blood supply is vital to the tumour growth, and it is 
needed by the tumour to grow beyond the size of a couple of millimetres, since the 
tumour microenvironment is often hypoxic. (Hanahan−Weinberg 2001, Koster et al. 
2005, Ruan et al. 2010) 
Tumour cells require nutrients, oxygen and the ability to discharge metabolic waste 
and carbon dioxide in order to live and multiply. These needs are addressed by 
tumour associated neovascularization (Margolin 2002). Cancer cells express growth 
factors that recruit new vasculature from existing blood vessels.  This process is 
promoted by tissue-resident macrophages, normally in the wound-healing subset but 
also in the tumour tissue setting. Tissue-resident macrophages or tumour-associated 
macrophages (TAMs) are equipped to remodel tissue and produce vascular 
endothelial growth factor (VEGF). In normal tissue there is a delicate balance 
between pro- and anti-angiogenic factors and it results in the creation and 
maintenance of the vascular network. In tumour tissue this balance is often 
disrupted, which results in chaotic and unorganized vasculature. (Ellis et al. 2008) 
Numerous pro-angiogenic factors have been characterized in normal tissue and also 
in tumours, but VEGF has been identified as a predominant regulator of tumour 
angiogenesis. (Folkman et al. 2005, Bergers et al. 2000) 
VEGF (also known as VEGFA) is a member of a larger family of growth factors that 
also includes VEGFB, VEGFC, VEGFD and placental growth factor (PLGF). 
VEGF has three essential mechanisms of action in the tumour vasculature. Early in 
tumour development, VEGF helps the establishment of new vasculature and this 
enables the formation of macroscopic tumours from isolated tumour cells. It has 
been shown that VEGF is able to stimulate tumour growth at both primary and 
metastatic sites through the recruitment of bone-marrow-derived progenitor cells 
that form the new vascular network. As the vascular network develops and the 
tumour grows, VEGF continues to help the new vasculature to grow further. The 
new blood supply can then further promote tumour growth and metastasis. 
Throughout the tumour life span, VEGF is present and enables the survival of the 
vasculature, allowing tumours to sustain their metabolic requirements. Therefore, 
VEGF is continuously expressed by the tumour cells and also by the surrounding 
microenvironment. (Folkman 2005, Hanrahan 2003) 
As the tumour grows larger and matures, also secondary angiogenic pathways are 
activated. These include basic fibroblast growth factor (bFGF), transforming growth 
factor beta (TGFβ), placental growth factor (PIGF), and platelet-derived endothelial 
cell growth factor (PD-ECGF). Although these secondary pathways emerge, VEGF 
continues to be expressed and remains the most critical mediator of angiogenesis. 
(Ferrara et al. 2005, Hicklin et al. 2005)  
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High levels of VEGF expression can be observed across a wide range of solid 
tumours and also in haematological malignancies (Fontanini et al. 1997, Rini et al. 
2005). High VEGF expression in the tumour tissue is connected with inferior 
survival in many malignancies, including DLBCL (Gratzinger et al. 2008 and 2010) 
Also, high levels of VEGF in the blood have been proven to be an adverse 
prognostic factor in chemotherapy-treated lymphoma patients (Salven et al. 1997, 
Salven et al. 2000) Also, as tumours are highly dependent on VEGF, and VEGF is 
continuously present throughout the cancer life cycle, angiogenesis and VEGF are 
rational targets for cancer treatment strategies. (Ruan et al. 2010, Medinger et al. 
2010) 
3.5.5 Tumour associated macrophages 
Ilya Metchnikoff won the Nobel Prize for Medicine for his identification and 
description of macrophages in 1908. Macrophages are a heterogeneous population of 
innate myeloid cells, white blood cells involved in health and disease. They are 
known to be the most functionally diverse cells in the hematopoietic system. 
Monocytic precursor cells migrate from the bloodstream to the tissues and have the 
ability to differentiate into macrophages, dendritic cells or foam cells depending on 
local cues in the tissue type. Macrophages are found in all tissues and serve as part 
of the immune system by engulfing and digesting cellular debris, foreign substances, 
microbes, cancer cells, and anything else lacking the types of proteins specific to the 
surface of healthy cells on its surface. This process is called phagocytosis. 
Therefore, tissue-resident macrophages take part in combating infections, resolving 
acute inflammation and regulating metabolic responses to stress. (Heusinkveld et al. 
2011, Gordon–Taylor 2005) 
Macrophages undergo specific differentiation depending on the tissue environment 
they are exposed to (Steinman−Idoyaga 2010). The presence of cytokines and the 
type of receptor interaction defines the various roles of macrophages (Gordon–
Taylor 2005). Two distinct states of polarized activation for macrophages have been 
identified: the classically activated (M1) macrophage phenotype and the 
alternatively activated (M2) macrophage phenotype (Gordon–Taylor 2005, 
Mantovani et al. 2002). As an oversimplification, classically activated macrophages 
(M1) are associated with acute inflammation and T-cell immunity, and M2 
macrophages with immune suppression. 
In normal tissues, granulocyte macrophage colony stimulating factor (GM-CSF) and 
macrophage colony stimulating factor (M-CSF) have a major role in promoting the 
differentiation of monocytes to macrophages (Jaguin et al. 2013). GM-CSF have 
been shown to polarize monocytes towards the M1 macrophage subtype with a “pro-
inflammatory” cytokine profile (e.g. TNF, IL-23), and treatment with M-CSF 
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produces an “anti-inflammatory” cytokine profile similar to M2 macrophages. 
Classically activated (M1) macrophages have the role of effector cells in TH1 
cellular immune responses. The alternatively activated (M2) macrophages appear to 
be involved in immunosuppression and tissue repair. (MacMicking et al. 1997, 
Mantovani 2010, Martinez et al. 2005) 
M1 phenotype is commonly adapted by macrophages in response to signals 
delivered by bacterial products or IFNγ. When the polarization occurs, these M1 
macrophages can phagocytise and kill target cells. M2 macrophages, on the other 
hand, develop in response to for instance IL-4 or IL-13. The M2 type expresses 
abundant scavenger receptors and is associated with high production of IL-10, IL-
1b, VEGF and matrix metalloproteinases and has therefore an important role in 
tissue healing and angiogenesis. M2 macrophages play a role in wound healing 
where there is a need to dampen immune responses. Macrophages also have a role as 
antigen presenting cells (APC) that express class I and class II HLA-molecules and 
co-stimulatory/inhibitory molecules to instruct T-cells. M1/M2 designations 
represent extreme ends of the scale and the concept is oversimplification. 
Macrophages display great plasticity and can adapt to a spectrum of activation states 
ranging between the M1 or M2 phenotype depending on the mix of signals in their 
direct microenvironment. Moreover, it has been shown that it is possible to 
reprogram fully polarized M1 and M2 macrophages in vitro towards the opposite 
functional phenotype by treatment with cytokines (Mosser et al. 2009, Gordon et al. 
2005, Dijkraaf et al. 2013) 
Macrophages are present in most human tumours and also contribute to tumour 
growth and progression. As described by Hanahan and Weinberg (2000, 2011), 
avoidance of immune destruction and tumour promoting inflammation are hallmarks 
in the development of cancer. Also, carcinogenesis is characteristically associated 
with macrophage-mediated inflammation. This emphasizes the role of macrophages 
in cancer. The presence of TAMs in the tumour tissue is often associated with poor 
prognosis. Tumour tissue is almost always hypoxic due to uncontrolled growth and 
this hypoxia and necrotic tumour cells promote chronic inflammation. In hypoxic 
conditions macrophages release inflammatory compounds such as tumour necrosis 
factor (TNF)-alpha, which leads to activation of nuclear factor-kappa B pathway 
(NF-κB). This results in production of proteins that stop apoptosis and promote cell 
proliferation and inflammation. (Allavena et al. 2008) Additionally, macrophages 
serve as a source for many pro-angiogenic factors including vascular endothelial 
factor (VEGF), tumour necrosis factor-alpha (TNF-alpha), granulocyte macrophage 
colony-stimulating factor (GM-CSF) and IL-1 and IL-6, all contributing further to 
tumour growth and longevity. (Murdoch et al. 2008) TAMs are traditionally 
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considered to acquire an M2 phenotype, contributing to tumour growth and 
progression. (Pollard 2004) 
The detection and identification of TAMs is somewhat complicated in the tumour 
setting since there is no single specific antibody for M1 and M2 macrophages. 
TAMs are often identified by the expression of transcriptional factors, cell surface 
markers, the production of cytokines and their function in vitro. The most commonly 
used antibody to recognize macrophages is the glycoprotein CD68. M2 macrophages 
express high levels of CD163, a haemoglobin-scavenger receptor, and this has been 
used to discriminate between M1 and M2 macrophages. The combination of MMPs 
and CD68 or CD163 has also been used to detect M2 macrophages in tumours. 
(Moestrup et al. 2004) To date, no unique markers for M1 macrophages have been 
described. Macrophages produce chemokines to attract other immune cells. The 
distinct type of these chemokines may offer help to distinguish between the 
macrophage subsets. For example, M2 macrophages attract immune cells by the 
production of CCL22 and CCL18. (Schraufstatter et al. 2012, Schutyser et al. 2005) 
Depending on the mode of activation, TAMs are able to promote tumour growth and 
suppress local immunity or attack tumour cells and sustain tumour immunity. This 
makes TAMs an attractive target for cancer therapies. Immunotherapeutic strategies 
include approaches focused on the attraction and polarization of M1 macrophages as 
well as on the reprogramming of macrophages as well as limiting macrophage 
recruitment and preventing protumour polarization. (Allavena et al. 2008, Squadrito 
et al. 2011) 
3.6 Biological prognostic factors 
So far we have learnt that although DLBCL is a single diagnostic entity, it comprises 
several distinct molecular subgroups differing in the expression of specific gene 
signatures and also in the oncogenic pathways involved. Why is the recognition of 
the aberrantly regulated genes so important? Because understanding the molecular 
framework provides a possibility to develop more specific markers for risk 
stratification and rationally targeted therapeutic approaches and ultimately cure more 
patients. Therefore it is sensible to contemplate the prognostic relevance of the 
biological factors relating to this heterogeneity. (Pasqualucci et al. 2014, Rui et al. 
2011, Lenz et al. 2008b) 
3.6.1 Cell of origin 
As discussed before, DLBCL can be divided into subgroups on the basis of GC and 
ABC biological subgroups that reflect the differentiation stage malignant cell is 
developed. These biological subgroups also differ in which signalling pathways are 
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activated. (Alizadeh et al. 2008) GCB subtype is generally associated with a 
favourable survival although this has been disputed in the immunochemotherapy era. 
Accordingly, ABC subtype has been associated with poorer survival. Although 
rituximab has improved the prognosis in all biological subgroups (Fu et al. 2008), 
patients with the ABC subtype have a lower chance of cure with current therapeutic 
agents, and are considered the new biologically defined poor-risk subset with unmet 
medical needs. 
PMBL expresses a gene signature similar to the malignant cells of Hodgkin 
lymphoma and the clinical course of the disease is also similar. It is considered a 
clinically favourable subgroup of DLBCL. (Pasqualucci et al. 2014, Rui et al. 2011, 
Lenz et. al 2008b, Rosenwald et al. 2003) 
3.6.2 TP53 
The TP53-gene is a tumour suppressor gene coding the wild type p53 protein. The 
p53 coordinates cell division, participates in the DNA repair process and activates 
the apoptosis in the cells unable to repair the damage. The p53 protein has the ability 
to regulate the expression of a large group of important genes for cell-cycle 
regulation. 
TP53 mutations are very common in solid tumours and found only in about 10–20% 
of DLBCL tumours. In DLBCL, other interferences of the p53 pathway may 
influence p53 function, such as MDM2, an important negative regulator of the p53. 
MDM2 mutations have been found in both GCB- and ABC-type tumours. Most 
mutations are found in the p53 binding sites and can inactivate the p53 protein. Such 
mutations have been indicated to correlate with inferior survival in both patients 
treated with immunochemotherapy and chemotherapy. (Young et al. 2007, Xu-
Monette et al. 2012) 
3.6.3 BCL-2 
BCL-2 (B-cell lymphoma 2) is an important protein in the B-cell development and 
differentiation. It also protects the cell from apoptosis. It was first discovered due to 
the involvement of the BCL2 gene in t(14;18) in follicular lymphoma. BCL-2 
overexpression is seen in 47–58% of the DLBCL tumours (Iqbal et al. 2006&2011, 
Visco et al.2013). 
In the pre-rituximab era, BCL-2 overexpression was found to be significantly 
associated with a higher relapse rate, worse disease-free and OS (Vaidya et al. 2014, 
Witzig et al. 2014) 
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BCL-2 overexpression is an adverse prognostic factor in immunochemotherapy-
treated patients with GCB-tumours but not when the tumour type is ABC-like. 
(Iqbal et al. 2011) In GCB subtype DLBCL the overexpression of BCL-2 is in most 
cases due to t(14;18) translocation. In these cases rituximab cannot affect the 
expression of BCL-2 or the inhibition of apoptosis. 
As mentioned above, t(14;18) translocation does not manifest itself in the ABC-
subtype. Instead, the BCL-2 expression is regulated via amplification of the BCL2 
gene and through the NF kappa B -pathway, one of the hallmarks of the ABC 
subtype. Rituximab attenuates the NF kappa B -pathway activity and this leads to 
reduction in BCL-2 and diminishes the protective effect in apoptosis. Thus also 
patients with ABC subtype tumours benefit from immunochemotherapy. (Iqbal et al. 
2006) Also, BCL2 inhibitors have been developed and are now in late-phase clinical 
trials in haematological malignancies. (Anderson et al. 2016) 
3.6.4 MYC 
MYC is a transcription factor involved in a number of cellular functions including 
cell growth and proliferation, metabolism, protein synthesis, DNA replication and 
angiogenesis. MYC-rearrangement (MYC-R) is the hallmark in Burkitt lymphoma 
(BL). It is primarily a genetic event and presents itself as simple karyotype and sole 
chromosomal abnormality in BL. Besides BL, MYC-R has also been identified in 
other lymphoid neoplasms. In DLBCL tumour samples, the incidence of MYC-R 
varies between studies but when measured with FISH seems to be in the range of 6–
14%. MYC-R has also been found in unclassifiable B-cell lymphoma, plasmablastic 
lymphoma, plasma cell myeloma and MCL.  In DLBLC MYC-R generally predicts 
an inferior outcome: prognosis when treated with R-CHOP is poor (<12 months 
OS). (Klapper et al. 2008, Savage et al. 2009, Barrans et al. 2010, Dominguez-Sola 
et al. 2012) Also, MYC-R+ patients respond poorly to second line therapies. 
(Cuccuini et al. 2012) 
3.6.5 MYC and BCL2: double hit lymphomas 
Recent evidence indicates that the adverse prognostic influence of MYC 
translocation increases manifold with the presence of BCL2 or BCL6 genetic lesions. 
These so-called double-hit (DH) lymphomas have extremely aggressive clinical 
features and poor clinical prognostic factors: a high IPI score, often bone marrow 
and CNS involvement and very often other extranodal sites. Previously, these 
lymphomas were often diagnosed as Burkitt-like DLBCL. These patients also 
respond very poorly to R-CHOP and the survival is most often less than a year. 
(Akyurek et al. 2012) Recently, a study by Copie-Bergman et al. (2015) 
demonstrated that the adverse prognostic impact of MYC-R is correlated to the 
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MYC-IG translocation partner gene. Also, their study suggested that MYC/BCL6 
may have a different biological meaning than MYC/BCL2 in DH tumours. The 
prognostic impact of MYC-DH was only observed in the GCB subtype. (Campo 
2015) 
It must be noted that in these studies the lesions have been detected by FISH. If the 
expression of the MYC and BCL2 proteins is studied by IHC, the co-expression is 
found in about 20–30% of DLBCL cases. This is much higher than the percentage in 
the patient series where FISH has been used and the frequency of DH lymphomas 
has been less than 10%. This suggests that mechanisms behind the protein 
overexpression are more complex than a mere translocation. Nevertheless, when the 
protein levels and survival are correlated, the survival remains poor to DH 
lymphomas, although not as dismal as when defined by FISH. In the report by Green 
et al., DLBCLs with a protein DH score of 2, defined by high expression of both 
MYC and BCL-2 protein, were significantly associated with shorter survival. (Green 
et al. 2012) Similar findings were confirmed by Johnson et al. in a study where 
presence of concurrent MYC and BCL-2 protein expression was associated with a 
significantly inferior 5-year OS of 36% versus 71% in those without MYC and 
BCL-2 co-expression (P < 0.05). (Johnson et al. 2012). Hu et al. showed that 
MYC/BCL2 co-expression occurs more often in the ABC subtype and suggested 
that this contributes to the inferior prognosis of ABC subtype patients. (Hu et al. 
2013, Horn et al. 2013) 
As the prognosis of the DH DLBCL patients is poor it would be reasonable to 
consider testing for MYC and BCL2 rearrangement by FISH for all newly diagnosed 
DLBCL.  The upfront use of more aggressive Burkitt-like chemotherapy regimens 
might be considerable in eligible patients but it is yet unknown whether these 
patients would benefit from intensified chemotherapy or targeted therapies. A recent 
study by Howlett et al. (2015) suggested that DH patients might benefit from 
addition of etoposide in to R-CHOP. Enrolment in clinical trials for DH lymphomas, 
if possible, at this point seems to be the best alternative. (Vaidya 2014) At present, 
routine IHC in defining overexpression of MYC and BCL2 is done in many Cancer 
Centers including Helsinki.  
3.6.6 Protein kinase C βII 
The protein kinase C (PKC) is a family of isoenzymes belonging to the extensive 
group of serine/threonine kinases. The PKC family is involved in several key 
cellular processes including cell proliferation, apoptosis and differentiation. The 
different isoforms of PKC address positive and negative effects on cell proliferation 
and survival, and altered levels of individual isoforms are implicated in cancer cells 
and other diseases. (Griner et al. 2007) 
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In cancer, PKCs are shown to have a role as receptors for carcinogenes and as 
second messengers for growth factors, such as vascular endothelial growth factor 
(VEGF) thus promoting tumour progression. Invasiveness of cancer cells has been 
shown to increase in the presence of PKCs. PKCs have also shown to be involved in 
the resistance to chemotherapy agents. The actual mechanism by which PKCs 
contribute to tumourigenesis remains unclear. In some studies, PKCs are suggested 
to have a role in phosphatidylinositol 3-kinase/AKT, the main pathway responsible 
for apoptosis regulation. Overexpression and increased activity of PKC has been 
found in many cancers, for example prostate, lung and colon carcinomas. (Koren et. 
al 2004, Su et al. 2002, Clark et al. 2003, Gokmen-Polar et al. 2001) 
PKCβs are commonly found in two isoforms: PKCβI is associated with 
differentiation and is downregulated in neoplasms. PKCβII, in turn, is involved in 
cellular proliferation and is overexpressed in cancer. The PKCβ isoform is also 
known to be an important mediator of vascular endothelial growth factor VEGF thus 
linking PKCs to angiogenesis. Increased invasion and proliferation of tumour cells 
has also been associated with PKCβ (Herbst et al. 2007). PKCs are also known to 
increase tumour invasiveness acting on adhesion, migration and matrix degradation 
of neoplastic cells. (Griner et al. 2007) 
In DLBCL, PKCβII is one of the most prominently overexpressed genes and is 
linked to poor prognosis in chemotherapy-treated patients (Hans et al. 2005, 
Espinosa et al. 2006, Schaffel et. al 2007) Therefore, based on the multifunctional 
role of PKCβII in cancer, the inhibition of individual PKC isoforms is also a 
potential target for cancer therapy and PKC inhibitors have undergone clinical trials 
in various cancers. 
3.6.7 Tumour microenvironment 
There is increasing evidence that tumour microenvironment (TME) and host 
immune response play an important role also in lymphoma progression and survival. 
The presence of gene expression signatures commonly associated with 
macrophages, T-cells, and remodelling of the extracellular matrix has been shown to 
have prognostic significance. (Monti et al. 2005) TME was discussed with more 
detail above. 
The gene-expression signature survival model generated by GEP studies underlines 
the importance of microenvironment. It distinguishes two gene signature profiles in 
regard of the TME, stromal-1 and stromal-2. These profiles reflect the character and 
the importance of the non-malignant cells in the DLBCL tumour.  
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The stromal-1 signature includes extracellular matrix encoding genes that are mainly 
expressed in many normal mesenchymal tissues. Another characteristic feature of 
stromal-1 type tumours is the infiltration by cells of the myeloid lineage. These 
include for example tumour-associated macrophages (TAMs), myeloid-derived 
suppressor cells, and Tie2-expressing monocytes. These cells are known for roles in 
suppressing T-cell immune responses and initiating angiogenesis. (Lenz et al. 
2008a) TAM number in the tumour tissue correlates with poor prognosis in 
numerous malignancies including cancers of breast, cervix, bladder and brain. Also, 
many studies suggest that a high number TAMs is advantageous for tumour growth 
and survival. (Heusinkveld et al. 2011)  Interestingly, new immunotherapeutic 
strategies utilize the immune system and thus macrophages can promote anti-
tumoural impact of therapy. 
In DLBCL the data has been contradictory. Some studies have found no impact of 
TAMs in the prognosis (Hasselblom et al. 2008), whereas some studies suggest 
TAMs are associated with poor survival (Wada et al. 2012). It must be noted that the 
patients in these small patient sets have not been treated uniformly with 
immunochemotherapy. A recent study suggested that increase in M2 macrophages 
correlates with inferior survival in R-CHOP treated DLBCL patients (Nam et al. 
2014). Also, tumour-resident lymphocytes and mast cells are suggested to have 
prognostic relevance in DLBCL (Keane et al. 2010, Hedström et al. 2007) 
The stromal-2 signature, on the other hand, reflects the “angiogenic switch” in 
which the progression of a hyperplastic lesion to a fully malignant tumour is 
accompanied by new blood vessel formation. Expression of genes coding for pro-
angiogenic factors is correlated with poorer survival. High VEGF expression levels 
have been observed across a wide range of solid tumours, including lymphomas. 
Expression of the VEGF ligand is observed across a range of tumour types and has 
been widely correlated with tumour development and also poor prognosis. (Ferrara 
et al. 2003, Bertolini et al. 1999, Niitsu et al. 2002, Salven et al. 1997 and 2000). In 
immunochemotherapy-treated DLBCL patients, VEGFR2 expression is associated 
with poor survival (Gratzinger et al. 2010). Also, high microvessel density has been 
reported to be an adverse prognostic factor in DLBCL treated with chemotherapy. 
(Cardesa-Salzmann et al. 2010 Gratzinger et al. 2008)  
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4 
4 Aims of the study 
 
The aim of this study was to define novel host and tumour related prognostic 
markers in the immunochemotherapy era of DLBCL. The main focus was on 
angiogenesis and tumour microenvironment. 
The specific aims were: 
1) To evaluate prognostic significance of tumour PKCβII expression in 
the immunochemotherapy era (I) 
2) To study the significance of tumour microvessel density in DLBCL 
prognosis (unpublished) 
3) To determine whether s-VEGF continues to have prognostic impact 
after the addition of rituximab to chemotherapy. (II) 
4) To investigate the prognostic impact of TAMs in DLBCL (III) 
5) To explore s-CCL18 and s-CD163 levels and their impact on survival 
in immunochemotherapy-treated DLBCL 
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5 
5 Material and methods 
5.1 Patients 
Multiple patient sets were used for the analyses. The patients were selected on the 
basis of the availability of clinical data and pretreatment tumour tissue or serum for 
the biological analysis. All the patients had de novo DLBCL. Patients with HIV 
positivity, CNS involvement at presentation and evidence of transformation from an 
indolent lymphoma, were excluded. Detailed descriptions of patient cohorts in 
different studies are provided in the original publications (I–III).  
Studies II and III were a part of a Nordic Lymphoma Group (NLG) phase II clinical 
study (NLG-LBC-04) and utilized the prospectively collected study population and 
pre-treatment serum and tumour tissue. The trial population consisted of previously 
untreated DLBCL patients. The treatment consisted of CNS prophylaxis with one 
course of high-dose methotrexate and one course of high-dose cytarabine followed 
by six courses of R-CHOEP-14. Patients were less than 65 years old and had a high-
risk disease according to age-adjusted International Prognostic Index (aaIPI 2 or 3). 
(Holte et al. 2013) 
Initially, NLG-LBC-04 study recruited 156 eligible patients with a histological 
diagnosis of DLBCL (92%), grade 3 follicular lymphoma (6%) or both (2%). The 
patient selection to our substudies II and III was based on DLBCL diagnosis and 
availability of pre-treatment serum samples, fresh frozen lymphoma tissue 
containing adequate material for gene expression profiling analyses and TMA 
samples for immunohistochemical studies. FL cases were excluded. Diagnoses were 
originally set by local pathologists as CD20 positive DLBCLs according to the 
WHO classification, and the samples reviewed by national pathologists. The GC and 
non-GC classification was determined according to the Hans algorithm. Clinical 
results of the trial have been published. (Holte et al. 2013) 
Lymphoma/Leukemia Molecular Profiling Project (LLMP) oligonucleotide based 
microarray data set and Cancer Genome Characterization Initiative (CGCI) RNA 
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sequencing data set were used as validation cohorts for the gene expression analysis. 
The LLMP data set (Lenz et al., 2008a; GEO dataset: GSE10846) comprises 233 R-
CHOP-treated DLBCL patients. Both clinical data and expression data are available 
online. The CGCI (dbGaP database applied study accession: phs000532.v3.p1) data 
set consists of RNA sequencing data from 92 immunochemotherapy-treated DLBCL 
patients and their clinical information. 
5.2 Immunohistochemistry 
Immunohistochemical stainings were performed on formalin-fixed paraffin-
embedded tissue sections. The sections were either a part of a tissue microarray 
(TMA) or individual slides. Samples were prepared as follows. At first, for 
dehydration the sections were incubated at 56 °C for 30 minutes. Deparaffinization 
was performed according to standard procedures. Antigen retrieval was done in an 
autoclave or in a microwave oven in sodium citrate. The samples were then washed 
with phosphate-buffered saline and incubated overnight at 4°C with the monoclonal 
antibody in question (antibodies used in IHC and the dilutions are listed in Table 7). 
Vectastain ABC kit (Vector Laboratories, Burlingame CA, USA) was then used to 
complete the stainings according to manufacturer´s instructions. Visualization with 
avidin-biotin-peroxidase method and counterstaining was performed with Mayer 
hematoxylin. The staining-positive cells were counted per high-power fields (hpf) as 
absolute cell numbers with microscope. Olympus BH-2 brightfield microscope 
(Olympus America Inc, Melville, NY,USA) and 1000x magnification was used in 
Study I and ten fields were counted on each slide. Leica DMLB lightfield 
microscope (Leica Microsystems GmbH) and 630x magnification was used in the 
rest of the studies and ten to five fields were counted on each slide. The mean score 
for each slide was then calculated.  In cases with uneven staining the areas showing 
higher positivity were analysed. Immunoreactivity and the scorings were determined 
without knowledge of the clinical data. The CD163 and CCL18 stainings in Figure 6 
serve as an example of the IHC stainings. 
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Figure 6 Examples of IHC. CD163 and CCL18 stainings: CD163- and CCL18-positive 
macrophages are displayed with red colour, while lymphoma cells are blue. 
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Table 7. Antibodies used in the study. 
Antigen Dilution Source Study 
PKC 1:200 Serotec I 
CD31 1:200 Novocastra Laboratories Unpublished 
CD68 1:2000 Dako Cytomation III 
CD163 1:70 Thermo Fisher Scientific III 
CCL18 1:200 R&D Systems III 
CD14 1:800 Leica Biosystems III 
CD3 1:600 Thermo Fisher Scientific III 
CD4 1:500 Thermo Fisher Scientific III 
CD8 1:600 Leica Biosystems III 
CD21 1:100 Leica Biosystems III 
CD57 1:200 Leica Biosystems III 
CGET 1:100 Abcam III 
 
5.3 Enzyme-linked immunosorbent assay (ELISA) 
Peripheral venous blood samples were collected in sterile test tubes before any 
therapy was given and after three cycles of immunochemotherapy. Samples were 
centrifuged at 3000 × g for 10 min, serum was separated from the blood cells and 
then stored at −70°C.  
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Soluble VEGF, CD163 and CCL18 were analysed from the serum samples using 
VEGF Quantikine ELISA (R&D Systems, Minneapolis, MN, USA), CD163 
Quantikine ELISA (R&D Systems, Minneapolis, MN, USA) and Duoset human 
CCL18/PARC development (R&D Systems, Minneapolis, MN, USA) kits, 
respectively. 
The ELISA assay employs a sandwich enzyme immunoassay technique. In the 
Quantikine ELISA kits the monoclonal antibody specific for VEGF/CD163 has been 
pre-coated onto a microplate by the manufacturer, whereas for the CCL18 kit, the 
capture antibody was first coated into a 96-well microplate. Standard and serum 
samples were pipetted into the wells and VEGF/CD163/CCL18 was captured by the 
immobilized antibody. After washing away unbound substances, an enzyme-linked 
polyclonal antibody specific for VEGF/CD163/CCL18 was added to the wells. 
Again, the unbound reagents were rinsed away and substrate solution was added to 
the wells producing colour in proportion to the amount of VEGF/CD163/CCL18 
bound in the initial step. The colour development was then stopped and the intensity 
of the colour was measured with microtiter plate reader (Multiscan Ascent version 
1.24 software, Thermo Labsystems, Basingstoke, UK) at 450 nm. Wavelength 
correction was set at 540 nm. The blank was subtracted from the duplicate readings 
for each standard and sample. A standard curve was generated for each set of 
samples assayed using standard and control readings. VEGF, CD163 and CCL18 
concentrations were determined at the point of intersection in the standard curve and 
the absorbance value. Concentrations are reported as pg/ml. All analyses and 
calibrations were carried out in duplicate. 
5.4 Gene and exon expression array 
Expression levels of exons and genes in this study were determined from the exon 
array-based data set of 32 pretreatment lymphoma samples from the patients treated 
in the Nordic phase II NLG-LBC-04 protocol.  Affymetrix Human Exon 1.0 ST 
arrays was used to obtain the array data as previously described (Chen et al. 2011). 
Hybridization protocols and raw expression microarray data are available at 
ArrayExpress archive (http://www.ebi.ac.uk/microarray-as/ae/ID: E-MEXP-3463). 
To confirm exon array data, microarray data sets generated by Lymphoma/Leukemia 
Molecular Profiling Project (LLMPP) and Cancer Genome Characterization 
Initiative (CGCI) were used. The LLMPP data set contains mRNA expression data 
from 233 DLBCL patients treated with combination of rituximab and CHOP-like 
chemotherapy. (Lenz et al. 2008a)  The CGCI data set contains the RNA sequencing 
data from 92 DLBCL  patients treated with immunochemotherapy. (CGCI; dbGaP 
database applied study accession: phs000532.v3.p1) (Morin et al. 2011 and 2013) 
 48 
 
 
5.5 Statistical methods 
Statistical analyses were carried out using Statistical software package SPSS 16.0–
18.0 for Windows (SPSS, Chicago, IL, USA). 
χ2-test was used in the evaluation of the differences in the frequency of the baseline 
factors. Reproductibility of immunohistochemical stainings was evaluated by Kappa 
value. Kaplan–Meier method was used for survival rate estimation and the log-rank 
test for the comparison of the differences between the subgroups. Univariate and 
multivariate analyses were performed according to the Cox proportional hazards 
regression model. Overall survival (OS) was determined from the time of diagnosis 
to death or the date of last follow-up. Failure-free survival (FFS) was calculated as 
the period between diagnosis and date of relapse or death of any cause and 
progression-free survival (PFS) as the period between diagnosis and disease 
progression.  
P-values were two-tailed. A significant level of probability was considered < 0.05.  
In study III and the unpublished studies a web based cut-off finder tool at 
http://molpath.charite.de/cutoffanalysis was utilized to determine the best prognostic 
cut-off level for survival (Budczies et al. 2012). 
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6 
6 Results 
6.1 Prognostic value of PKCβII in immunochemotherapy-
treated DLBCL patients  
PKCβII is one of the most prominently overexpressed genes in DLBCL and it is 
linked to poor prognosis in chemotherapy-treated patients (Hans et al. 2005, 
Espinosa et al. 2006,Schaffel et. al 2007) In study I our aim was to determine if 
PKCβII has prognostic significance in the immunochemotherapy era. The patients 
were selected upon the availability of pre-treatment tumour samples for 
immunohistochemical analysis. The study included 95 patients treated with R-
CHOP or R-CHOEP regimen. The median age of the cohort was 61 years (range 18–
84 years). The median follow-up was 43 months (range 16–75 months). 17 patients 
had died at the time of last follow-up. The 3-year OS and FFS rates for the entire 
group were 84 and 76%, respectively. 
Stainings with PKCβII-antibody were performed on formalin-fixed paraffin-
embedded tissue sections. The results showed variation from a complete absence of 
PKCβII expression to intense reactivity. PKCβII immunoreactivity was localized to 
lymphoma cell membrane and cytoplasm. The quantity of PKCβII-positive 
lymphoma cells was first calculated and then the patients were further divided into 
two subgroups based on immunohistochemically defined PKCβII.  
The median level for PKCβII-positive lymphoma cells per high power field was 
found to be 16 (range 0–76). When the lowest tertile was used to divide the patients 
into PKCβII-low and PKC-βII-high groups, no significant differences were observed 
in the frequency of clinical characteristics between the groups, apart from the 
PKCβII-low group´s tendency to contain more females than males. Conversely, the 
PKCβII-high group tended to have more males. The patient characteristics were also 
correlated in relation to COO subgroups. The distributions of GC and non-GC 
phenotypes according to Hans algorithm, modified ABC-classification, and BCL-2 
positivity were studied and no association between these subgroups and PKCβII 
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expression was found. The relationship of PKCβII with patient and baseline 
characteristics is featured in Table 1 of the original article. 
When we correlated the immunohistochemical PKCβII expression and the survival, 
a significant correlation was observed. In Kaplan–Meier analyses, the lowest tertile 
(33%) values were found to be the best discriminator between the subgroups with 
different outcomes. The 3-year OS was 94% among the patients who had low 
PKCβII expression (≤33%, n=32), and 76% when the expression was high (>33%, 
n=63; P=0.036). Likewise, the FFS rates for the patients with low and high PKCβII 
expression were 84% and 70% (P=0.108). Together, the results suggested that the 
expression of PKCβII in the lymphoma tissue correlated with the survival of 
DLBCL patients treated with rituximab and chemotherapy. (Figure 7) 
Subsequently, we analysed the survival according to IPI score. The 3-year OS for 
the patients with low IPI (0–2) at diagnosis was 88%, and for the ones with high 
scores (3–5) 76% (P=0.029). To determine whether PKCβII expression could 
improve the prognostic value of the IPI, we estimated the PKCβII-related OS 
separately for the patients with low and high IPI scores. After stratification, PKCβII 
expression retained its prognostic impact on OS (P=0.074), but the difference was 
more evident in the subgroup of patients with high IPI score. 
To analyse whether immunohistochemically defined subtypes had prognostic impact 
in the study cohort rates, analyses according to Hans algorithm (Hans et al. 2004) 
and modified activated B-cell classification (Nyman et al. 2009) were estimated. No 
difference in survival was observed between GCB and non-GCB phenotypes 
(P=0.947) when Hans algorithm was used. With modified activated B-cell 
classification, there was a trend toward an inferior OS in ABC-group  
(P=0.064).When we adjusted the PKCβII-associated outcome for the activated B-
cell classification, the inferior OS rates were seen in both ABC and other patients 
(P=0.030) 
The PKCβII expression was then included to a multivariate survival analysis 
together with the IPI scores. In this prognostic model, both factors remained 
borderline significant indicators for overall survival (IPI, risk ratio=2.45; 95% CI 
0.93–6.47; P=0.070; PKCβII expression, risk ratio=3.77; 95% CI 0.86–16.62; 
P=0.079). 
To validate our immunohistochemical results, we analysed the prognostic 
significance of PKCβII mRNA expression from the LLMPP microarray data set. 
Consistent with the protein analyses, the cut off level for the lowest tertile (33%) 
was found to best distinguish the outcomes between the low and high PKCβII 
expression subgroups (Table 2 of the original article). The 3-year OS for the patients 
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with low PKCβII mRNA levels (≤33%, n=77) was 84% compared with 68% of 
those with higher levels (>33%, n=156; P=0.005). 
To study the association of PKCβII mRNA expression with molecular subtypes, the 
LLMPP patients with the unclassified molecular subtypes (n=33) were excluded 
from the analyses. Accordingly, the OS rates in the remaining 200 patients for the 
low and high PKCβII subgroups were 84% and 64% (P=0.002). When the PKCβII-
associated survival was stratified according to molecular subtypes, the difference in 
OS rates was observed both in the GCB and ABC subgroups (P=0.024). In 
multivariate analysis, both factors had independent prognostic significance for OS 
(PKCβII expression (low vs high), risk ratio=2.22; 95% CI, 1.102–4.463; P=0.026; 
COO (GCB vs ABC), risk ratio=2.90; 95% C1.600–5.244; P<0.001). 
 
Figure 7.Schematic drawing of the relevance of PKCβII to survival 
6.2 Microvessel density in R-chemo-treated DLBCL 
The PKCβII is known to be an important mediator of VEGF thus linking PKCs to 
angiogenesis and vasculogenesis (Griner et al. 2007, Herbst et al. 2007). Also, in 
GEP studies the stromal-2 signature DLBCLs were associated with increased 
tumour blood-vessel density and also a poorer survival after therapy (Lenz et al. 
2008a). We next investigated the association of MVD of the DLBCL tumour with 
the survival of patients after immunochemotherapy. The study population comprised 
76 patients treated with R-CHOP/R-CHOEP-like regimens in HUCH. The median 
age of this patient cohort was 60 years (range 23–80 years). The median follow-up 
was 69 months (range 3–133 months). Of the patients, 28 had relapsed and 28 died 
at the time of last follow-up. The 5-year OS and PFS rates for the entire group were 
62% and 57%, respectively. Stainings with CD31-antibody were performed and 
CD31-positive microvessels were counted. The results showed variation from 
almost a complete absence of microvessels to very high immunoreactivity. We 
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further studied MVD data together with the survival data. The optimal cut-off level 
was defined with ROC analysis to be 72%. When this cut-off was used in KM 
analysis, there was a trend toward a better PFS in the high MVD group. At 5 years, 
PFS was 68% in the high MVD group and 60% in the low MVD group (Figure 8). 
No difference in OS could be detected between the groups. Furthermore, CD68 and 
CD163 IHC data (TAM counts) was available on 38 of the patient population. No 
correlation could be found between MVD and these macrophage markers or PKCβII 
expression of the lymphoma tissue. 
 
 
Figure 8. PFS according to high and low MVD levels. The difference is not statistically 
significant. 
6.3 Pre-treatment serum VEGF levels and their association 
with prognosis in patients treated with 
immunochemotherapy 
Since angiogenetic gene signature is associated with poor survival in DLBCL (Lenz 
et al. 2008a) and VEGF is the most important mediator of angiogenesis, we wanted 
to include VEGF in our study.  In this study our aim was to determine whether 
serum VEGF levels and VEGF gene expression in the tumour tissue are associated 
with survival of R-chemo-treated DLBCL patients. 
Study population consisted of previously untreated DLBCL patients treated in a 
Nordic phase II protocol (NLG-LBC-04). The patient selection was based on the 
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availability of pre-treatment serum samples (n=102) and frozen lymphoma tissue 
containing adequate material for RNA analyses (n=32).  
The median age of the study population was 54 years (range 18–65) and at the time 
of the analysis, the median follow-up time was 40 months (range 16–71 months). In 
total, 23 patients had experienced progression or a relapse and 21 had died at the last 
time of follow-up. Fourteen of the deaths were lymphoma-related. The three-year 
PFS was 77% and OS 81%.  
Pre-treatment serum-VEGF levels were measured using VEGF Quantikine ELISA 
kit. The levels showed a great variation from undetectable to ≥2000 pg/ml, median 
concentration being 538 pg/ml. Ten patients had values higher than the highest 
standard of the kit ( 2000 pg/ml). 25% had s-VEGF level higher than 947 pg/ml 
which was the highest quartile. When this highest quartile was used as a cut-off 
value between two groups (low versus high), high s-VEGF level was associated with 
high aaIPI score and poor performance status. No differences in gender, LDH level, 
bulky disease, or lymphoma subtype were observed between the low and high s-
VEGF subgroups.   
High s-VEGF levels were associated with poor PFS. In univariate analysis using s-
VEGF levels as continuous variables, s-VEGF was found to have a prognostic 
impact on PFS (P=0.050). The risk of progression or relapse was 3.1 fold higher 
among the patients with high s-VEGF level in comparison to patients with low s-
VEGF levels (the highest quartile, 95% CI 1.34-6.91, P=0.008). According to 
Kaplan–Meier analyses, PFS at three years for the patients with high VEGF levels 
(the highest quartile; >947 pg/ml) was 59% compared with 83% for those with low 
VEGF levels (P=0.005). 3-year OS was 75% in the high s-VEGF group and 83% in 
the low s-VEGF group, respectively (P=0.739).   
The molecular subtypes of the study population were defined by the national 
pathology review based on immunohistochemistry and the Hans algorithm. 
Immunohistochemically defined non-GC or GC status was available for 77 patients. 
Of these, 26 patients were classified as non-GC and 51 as GC subtype. Non-GC 
group tended to have higher s-VEGF levels (P=0.055), but no differences in survival 
were seen between the groups. When adjusted for molecular subgroups, the s-VEGF 
level remained a prognostic factor for PFS (P=0.034). We further analysed the s-
VEGF-related PFS rates separately for the patients in different molecular subtypes 
and observed that there was a difference in three-year PFS between the s-VEGF high 
and low subgroups in the non-GC group (50% vs 88%, P=0.028). In the GC group, 
no significant difference in the outcome was seen (49% vs 78%, P=0.362).  
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Age-adjusted IPI was not significant prognostic indicator for PFS in the study 
population (P=0.167). 3-year PFS rates were 80% and 69% in the aaIPI 2 and aaIPI 
3 subgroups (P=0.160) and 3-year OS rates 84% and 73%, respectively (P=0.193). 
When adjusted for aaIPI, high s-VEGF level maintained its prognostic impact on 
PFS (P=0.011). Furthermore, when the s-VEGF-related PFS was analysed 
separately for the patients with low and high IPI scores, no difference in PFS was 
seen in either IPI 2 or IPI 3 subgroups.  
Next, we addressed the question whether there is an association between VEGF gene 
expression in the lymphoma tissue and survival. The gene and exon expression data 
were available from 32 patients of the trial population. (The baseline characteristics 
of the cohort are provided in the original publication).  Data were analysed both at 
the exon and gene expression levels with similar results. VEGF-A gene expression 
assessed as a continuous variable was found to correlate with VEGF receptor 1 
(VEGFR1, P=0.003) levels. Furthermore, VEGFR1 expression correlated with 
VEGFR2 (P=0.019), VEGFR3 (P=0.026), and ANGPT2 (P<0.001) levels. In 
contrast, no correlation between lymphoma tissue VEGF-A gene expression and s-
VEGF levels was found. We further studied the association between the gene 
expression of angiogenic factors, including VEGF-A. None of these correlated with 
the survival rates.  
Again, as a validation population, we used microarray data generated by LLMPP . 
Consistent with our own exon array data, no correlation between the VEGF-A or 
other studied angiogenic factors and survival was found. Neither was there any 
association between VEGF-A levels and the molecular subtypes.  
Together, the data show that s-VEGF levels, but not tumour derived VEGF, have 
prognostic value in DLBCL patients in the rituximab era.  High serum VEGF-level 
is an adverse prognostic factor in immunochemotherapy treated high-risk DLBCL 
patients but the VEGF expression in the lymphoma tissue correlates with serum 
levels nor the treatment outcome. (Figure 9) 
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Figure 9 Schematic drawing of the association of VEGF with survival. 
6.4 Prognostic significance of tumour associated 
macrophages in R-chemo-treated DLBCL 
In study III, we wanted to investigate the prognostic significance of TAMs on 
survival. As in previous studies, we combined the immunohistochemical data 
showing the protein expression of the TAM markers and gene expression data of the 
same markers. CD68 is known to be a “panmacrophage marker” expressed both on 
classically activated  M1 type and alternative M2 type macrophages whereas CD163 
and CCL18 are primarily recognized as markers of M2-type macrophages.  
Several patient cohorts were also used to validate the results. Again, we used the 
exon array data of 38 patients available from the Nordic phase II NLG-LBC-04 
study. For immunohistochemistry we had tumour tissue TMA from 59 trial patients. 
All samples were collected prior to treatment. As mentioned previously, patients 
were treated with R-CHOEP –immunochemotherapy regimen followed by systemic 
CNS prophylaxis. The cohorts were smaller than in the original study due to tissue 
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availability, but there were no major differences in the baseline characteristics of the 
patients included in this substudy. This implies that these cases were representative 
of the whole trial. 
Median follow-up was 65 months for both gene expression and TMA cohorts. In the 
gene expression cohort (n=38), nine patients had relapsed and nine died. Two of the 
deaths were not lymphoma-related.  Five-year PFS and OS rates were 72% and 76%. 
In the TMA cohort (n=59), the number of relapses and deaths were 16 and 11. One 
of the deaths was not lymphoma-related. Five-year PFS and OS rates were 72% and 
85%, respectively. Patient characteristic for all the cohorts are presented in the 
original publication. 
To address the question whether there is correlation between survival and gene 
expression of CD68, CD163, and CCL18 in the lymphoma tissue, we utilized exon 
array database. Not surprisingly, CD68 expression was found to correlate with 
CD163 (rs=0.574, p<0.001) and CCL18 (rs=0.426, p=0.008) mRNA levels. When 
the association between gene expression and survival was analysed, high CD68 
mRNA levels were found to have a favourable impact on PFS (p=0.016; no 
prognostic significance for OS, p=ns). No association between CD163 or CCL18 
expression and survival was discovered. According to Kaplan–Meier analysis 
utilizing the optimal cut-off level of 37%, the 5-year PFS for the patients with high 
CD68 mRNA levels was 83% as compared with 43% for the patients with low 
CD68 expression (p=0.009). Respectively, 5-year OS rates were 83% and 63% but 
the difference was not statistically significant (p=ns). We then compared the clinical 
characteristics of the patients to CD68 expression, but no significant differences in 
age, gender, aaIPI scores, or molecular subtype were detected between the 
subgroups.  
In order to find support for our CD68 expression data, we analysed the prognostic 
significance of CD68 gene expression in two separate patient sets available, CGCI 
and LLMPP. Supporting our original results, in the CGCI cohort high CD68 
expression also predicted favourable OS (p=0.033). When the optimal cut-off level 
of 35% was defined and used to discriminate the outcomes between the low and 
high CD68 subgroups, 3-year OS for the patients with high CD68 mRNA levels was 
86% compared with 67% for those with low CD68 levels (p=0.040). When the 
original cut-off level (37 %) defined in the first subset of patients was used, the 
differences between the low and high CD68 subgroups were borderline significant 
(0.071). In the LLMPP data set with the optimal cut-off level of 23%, 5-y OS rates 
were 72% and 58% for the patients with high and low CD68 mRNA levels, 
respectively (p=ns;). In this cohort the PFS data was not available. 
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Next, we analysed the prognostic impact of CD68+ TAM content in the tumour 
tissue on survival in the Nordic phase II study population.  Tumour tissue for TMAs 
and immunohistochemistry was available for 59 patients. TMAs were stained with 
CD68, CD163 and CCL18 antibody and positive TAMs were counted. Number of 
CD68+ TAMs was found to correlate with CD68 gene expression (rs=0.584, 
p=0.009) and CD163+ TAM counts (rs=0.780, p=0.001). Likewise, CD163+ TAM 
counts correlated with CD163 (rs=0.857, p<0.001) and CD68 (rs=0.597, p=0.005) 
gene expression.  CD68-stainings and counts were performed in two separate 
laboratories and there was a good concordance for CD68+ TAM analyses between 
the laboratories (rs=0.770, p<0.001). 
The median level for CD68+ TAMs/hpf was 37 (range 5–95). Again, the optimal 
cut-off level to discriminate the subgroups with different outcomes was found to be 
26 TAMs/hpf corresponding to 17% of the tumour samples. According to Kaplan–
Meier analysis, the patients with high CD68+ TAM counts had a 5-year PFS of 74% 
in comparison to 40% for those with lower CD68+ TAM counts (p=0.003), and also 
a better 5-year OS (90% vs 60%, p=0.009). (Figure 1. of the original publication) 
When multivariate analysis with aaIPI was performed, low CD68+ TAM count 
maintained its adverse prognostic value on OS (CD68+ TAM, RR=5.037 (95% CI 
1.329–19.088), p=0.017; IPI, RR=3.981 (95% CI 1.024–14.578), p=0.046). No 
differences in stage, IPI scores or molecular subgroups were found between low and 
high CD68+ groups.   
We also wanted to investigate the importance of other reactive microenvironmental 
cells in the lymphoma tissue and their significance on survival. In order to do this, 
we selected the following markers: pan-T-lymphocyte marker CD3 (chains e, d and 
g), T-helper cell antigen CD4, cytotoxic T-cell antigen CD8 (chains a and b), 
monocyte antigen CD14, follicular dendritic cell marker CD21 and NK cell marker 
CD57, as well as GCB cell marker GCET1. The mRNA levels were analysed and 
immunostained and positive cells quantified. For all markers, a correlation was 
found between the gene expression levels and the corresponding cell counts. Also, 
CD14+ cell counts correlated with CD68+ TAMs.  Gene expression levels or any of 
the cell counts of these markers did not show association with survival. 
In the NLG trial patient population, high CD68+ TAM content served as a 
prognostic marker for survival. In order to validate the results, samples from an 
independent population-based set of 72 immunochemotherapy-treated DLBCL 
patients were analysed for TAM content and survival. The patients were treated with 
immunochemotherapy in the HUCH. The baseline characteristics of this validation 
cohort are listed in Table 2 of the original publication. Immunohistochemical 
stainings were performed on individual whole tissue sections instead of a TMA 
based analyses, otherwise the analytics were identical with the previous study. 
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Again, connection between the TAM content and survival was found. In this tumour 
sample set, the median level for CD68+ TAMs/hpf was 33 (range, 13–67). The cut 
off level of 43 CD68+ TAMs/hpf, corresponding to the 76% of the patients, was 
found to best discriminate between the subgroups with different outcomes. No 
differences were observed in age, stage, IPI scores or molecular subgroups between 
low and high CD68+ TAM groups with this cut-off level. The relation between 
CD68+ TAMs and baseline characteristics are shown in Table 2 of the original 
publication. 
According to Kaplan–Meier analysis, 5-year PFS rates were 88% and 65% for the 
patients with high and low number of CD68+ TAMs (p=0.050) and the 
corresponding OS rates were 88% and 72%, respectively (p=ns). The risk of relapse 
was found to be 3.7 fold in the low CD68+ patient group (95% CI 0.903–16.462, 
p=0.068) and 2.5 fold for the patients with high IPI scores (CI 95% 1.104–5.492, 
p=0.028). When studied with multivariate analyses against IPI, the negative 
prognostic impact of low TAM content on PFS was found to be borderline 
significant (RR 4.1, 95% CI 0.948–17.309, p=0.059; for IPI, RR 2.6, 95% CI 1.149–
5.722 p=0.021). The clinical outcomes according to treatment and CD68+ TAM 
content in the validation cohort are shown in Fig. 3 of the original publication. 
Previous studies have shown that in most cancers, high TAM content relates to 
inferior survival (Heusinkveld et al. 2011). We therefore continued the study by 
evaluating the prognostic impact of TAMs on the outcome of 50 DLBCL patients, 
who received therapy before rituximab was available in clinical routine 
(prerituximab era). The patient characteristics of the prerituximab cohort are shown 
in Table S3 of the original publication. The cohort consisted of 30 patients who had 
received HDT and ASCT as a consolidation after their first line therapy, and 20 
patients who received it as a salvage therapy for relapsed disease. Again, 
immunohistochemistry was performed on whole tissue sections. In this population, 
median number of CD68+ TAMs/hpf was 58 (range 19–83) and no differences were 
observed in baseline characteristics between high and low CD68+ TAM subgroups 
(Table S3 of the original publication). Survival and TAM count were then analysed 
using Kaplan–Meier estimates (Figure S1 of the original publication). The patients 
with low CD68+ TAM content had better 5-year PFS and OS rates when compared 
to patients with high CD68+ TAM counts (72% vs 40%, p=0.021 for PFS and 72% 
vs 39%, p=0.015 for OS). The patients were further divided into two groups 
according to the time of ASCT. It was discovered that the patients treated with HDT 
as salvage therapy and with low CD68+ TAM counts at diagnosis had significantly 
better OS than the ones with high counts, (70% vs 13%, P=0.020). A non-significant 
difference was also observed in the patients who were treated with ASCT and HDT 
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in frontline (80% vs 47%, P=0.083).  The results confirm previous findings on 
chemotherapy treated DLBCL patients (Cai et al. 2012, Wada et al. 2012).  
Based on our results, the prognostic value of macrophages seems to switch when the 
patients receive immunotherapy. Therefore, we wanted next to evaluate the impact 
of therapy on TAMs in the tumour tissue.  We analysed the expression of 
macrophage markers and the number of TAMs from ten DLBCL sample pairs 
collected before the treatment and one day after the first chemoimmunotherapy 
infusion was finished. The comparison of pre- and post-treatment tissue samples in 
this small cohort of patients showed an increase in mRNA levels of CD68 
(p=0.052), CD163 (p=0.023) and CCL18 (p=0.042) genes in response to 
immunochemotherapy (Figure 4A of the original publication). Consistent with the 
gene expression data, we observed a significant increase in the number of CD68+ 
TAMs (53 vs 68, p=0.023) (Figure 4B of the original publication), and a non-
significant increase in the CD163+ TAM counts (67 vs 77). In comparison, an 
increase in the CD3 (CD3e, p=0.003; CD3d, p=0.010; CD3g p=0.013), CD4 
(p=0.021), and CD8 (CD8a, p=0,009) mRNA levels was also detected in response to 
therapy, while CD20 and CD21 levels did not show significant changes. 
Together, the data derived from different patient sets and techniques suggests that 
addition of rituximab to chemotherapy reverses the negative prognostic impact of 
high CD68+TAM content to favourable. (Figure 10) 
 
Figure 10. Schematic drawing of the significance of TAMs on survival. 
6.5 Serum CD163 and CCL18 levels in DLBCL patients 
Since the prognostic role of TAMs appeared to be dependent on what kind of 
therapy the patients had received, we wanted to explore the serum levels of 
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macrophage antibodies before and after immunochemotherapy. CD163 and CCL18 
levels in serum were measured at diagnosis prior treatment and then again, after 
three treatment cycles with R-CHOEP. NLG-04 trial population served as the patient 
set for this study. Pretreatment serum samples of 105 patients were available for 
CD163 analysis and 101 for CCL18 analysis. Serum levels of CD163 after three 
treatment cycles could be measured from 34 patients and CCL18 levels from 45 
patients.  
Serum levels were measured using ELISA. The pre-treatment levels showed 
variation and the median was 990 pg/ml (447–2365) for CD163 and 231 pg/ml (0–
893) for CCL18, respectively. After three treatment cycles, the median of both 
substances was lower, 748 pg/ml (511–749) for CD163 and 155 pg/ml (0–358) for 
CCL18. 
We next studied the association of s-CD163 and s-CCL18 in survival. Cut-off levels 
were set using Charite´s Cutoff Finder available online (Budczies et al. 2012). For 
CD163 cut-off was set at 14% for baseline levels and the same cut-off was used for 
levels after treatment. For CCL18, the level was 11%. When these cut-off values 
were used and studied together with gender, LDH level and IPI scores, no 
differences between the groups were found with one exception. High baseline s-
CD163 was found to be more common among male patients (p=0.026).  
We further studied the differences in the survival rates between the groups. Low 
CCL18 level and poor PFS was found to correlate. According to KM analyses, PFS 
at three years for the patients with low CCL18 levels before the treatment was 46% 
compared with 71% for those with high CCL18 levels (P=0.020). 3-year OS was 
72% in the low s-CCL18 group and 80% in the high s-CCL18 group (P=0.700).  
Interestingly, even with a smaller sample size, when measured after three treatment 
cycles, low s-CCL18 level remained a poor prognostic factor for PFS. 3-year PFS 
for the patients with low CCL18 levels after treatment was 50% compared with 71% 
for those with high CCL18 levels (P=0.051). 3-year OS was 82% in the low s-
CCL18 group and 85% in the high s-CCL18 group (P=0.840). (Figure 11 A)  Also, 
in univariate analysis s-CCL18 level after 3 treatment cycles as a continuous 
variable was found to be a statistically significant prognostic factor for PFS 
(P=0.031). 
Patients with low s-CD163 level at baseline tended to have inferior survival 
compared to those with higher levels. 3-year PFS for the patients with low CD163 
levels before treatment was 47% compared with 72% for those with high CD163 
levels (P=0.071) (Figure 11 B). 3-year OS was 79% in the low s-CD163 group and 
85% in the high s-CD163 group (P=0.645).  
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Figure 11. PFS according to baseline  s-CCL18 levels (A) and s-CD163 levels (B) 
We also studied the correlations between serum levels and the available gene 
expression and IHC results. There was a strong correlation between the baseline s-
CD163 and s-CCL18 levels (rs= 305, P=0.002). Also, baseline s-CD163 and s-
CCL18 correlated with CD163 expression in the tumour detected by IHC (rs=0.399, 
P=0.05 and rs=0.309, P=0.041). Interestingly, baseline s-CD163 also correlated with 
the CCL18 gene expression in the tumour. No correlation was found between s-
CD163 and s-CCL18 and the s-VEGF levels measured in the sera or VEGF 
expression in the tumour. Baseline blood monocyte count was also available for 28 
patients and it was found to correlate with baseline s-CCL18 and CCL18. 
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7 
7 Discussion 
DLBCL is a heterogeneous disease including various subtypes that differ from each 
other both biologically and clinically. GEP and genome-wide sequencing studies 
have over the last decade revealed various DLBCL subtypes and the high 
complexity of the DLBCL genome. The research in DLBCL has been particularly 
interesting because of the revolution of therapy with the induction of rituximab, one 
of the first antibodies ever used in the clinic. Rituximab was introduced almost two 
decades ago and the understanding of the biology of DLBCL has evolved 
extensively ever since. Indeed, we understand now that DLBCL is a heterogenous 
group of diseases that differ from each other extensively, rather than being a single 
homogenous entity. These distinctions can be portrayed on the genomic level, on the 
distinct pathways activated or by the clinical course of the disease.  
The real ongoing challenge is to identify the subtypes in the clinical setting and to 
find feasible regimens to treat the patients subtype-specifically. Approximately 70% 
of patients can be cured with conventional immunochemotherapy. For the remaining 
30%, prognosis remains poor and new treatment strategies are imperative. 
In the substudies of this thesis, new prognostic factors were identified in the DLBCL 
patients treated in the immunochemotherapy era. All of these prognostic factors are 
potential targets of therapy and have also been studied as such, either in the trial 
setting or in the preclinical models. 
7.1 PKCβII 
High PKCβII expression in the lymphoma cells has been identified before as an 
adverse prognostic marker in chemotherapy treated patients (Hans et al. 2005, 
Espinosa et al. 2006, Li et al. 2007, Schaffel et al. 2007). In our study, we showed 
that high expression of PKCβII serves as a poor prognostic marker at both protein 
level and gene expression level in DLBCL patients treated with rituximab-
containing regimens. The study was retrospective in nature, and the IHC population 
was quite small but the results could be validated in two distinct patient sets with 
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two different techniques. Also, the cut-off level used, the lowest tertile, was the 
same in both patient cohorts. A comparison of these results with previous 
immunohistochemical studies is more complicated since the cut points that best 
discriminate the low and high or negative and positive subgroups have varied 
considerably (from 5% to 50%) in these series. (Espinosa et al. 2006, Hans et al. 
2005, Schaffel et al. 2007) This is probably due to the difference in techniques, and 
if PKCβII IHC was to be used in clinic, a better standardization of the 
immunohistochemical methodology would be essential.  
PKCβII is among the genes differentially expressed in DLBCL tissue of the patients 
who are not cured with standard chemotherapy (Shipp et al. 2002).  Since high 
PKCβII levels remains an adverse prognostic factor in patients treated with or 
without rituximab, it is possible to suggest that rituximab does not interfere the PKC 
signalling. The mechanism by which PKCβII expression impairs the survival is 
unknown but is likely to be related to its capacity to activate signalling pathways 
that are critical for proliferation and angiogenesis. (Graf et al. 2005)  
Our results were of particular interest because at the time of the study, Enzastaurin, a 
PKCβ–selective inhibitor was undergoing clinical trials in DLBCL combined with 
immunochemotherapy. Enzastaurin was promising since in vitro studies had shown 
that DLBCL cells treated with it undergo apoptosis (Su et al. 2002) and subsequent 
phase II clinical study exhibited single-agent activity in relapsed/refractory DLBCL 
(Robertson et al. 2007). Unfortunately, the phase III Prelude study, comparing 
Enzastaurin with a placebo, failed to show a statistically significant increase in 
disease-free survival in patients at high risk of relapse following rituximab-based 
chemotherapy. (Crump et al. 2016)  PKCβII is downstream from multiple signalling 
pathways, including NF-kappaB and BCR (Saijo et al. 2002, Su et al. 2002) and has 
a role in VEGF signalling leading to angiogenesis. Therefore, PKC-signalling and 
its effects are complex and this might explain why a simple inhibition does not have 
a significant effect on survival of the patients. Also, therapeutic targeting of the 
PKCβII-NF-κB signaling pathway is activated in the tumour microenvironment 
(Lutzny et al. 2012). This may explain why patients did not benefit from Enzastaurin 
following immunochemotherapy: there was no TME left for PKC-signalling. 
7.2 MVD and VEGF 
Since PKCβII is also a regulator of angiogenesis (Graf et al. 2005, Griner et al. 
2007) and angiogenesis is a potential and also widely used target for cancer therapy 
in various solid tumours, we wanted to examine the prognostic relevance of tumour 
vasculature and VEGF. VEGF is the key regulator of angiogenesis and 
bevacizumab, and VEGF antibody has therapeutic potential and is in clinical use in 
various cancers. (Ferrara et al. 2003, Nowak et al. 2008) The GEP studies have 
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identified a poor prognosis DLBCL gene signature profile, “stromal-2” type 
reflecting tumour blood vessel density (Lenz et al. 2008a). Angiogenesis has been 
studied as a target for therapy also in DLBCL.  We first examined whether MVD in 
DLBCL tissue has prognostic impact on survival in the immunochemotherapy era. 
No significant difference in the survival was found according to MVD levels, 
although our results showed a trend towards superior survival in the high MVD 
group. The cohort size was quite small, only 76 patients, and the study was 
retrospective in nature. Multiple studies addressing the relevance of MVD in the 
prognosis of NHL have been published. The results have been contradictory with 
some studies suggesting superior and others inferior survival related to high MVD. 
(Cardesa-Salzman et al. 2011, Koster et al. 2007, Jørgensen et al. 2007, Taskinen et 
al. 2010, Jelicic et al. 2016) This is likely to reflect the difficult interpretation of 
CD31 immunohistochemistry and also the fluctuation of vasculature areas especially 
in DLBCL tumours. 
In study II, we measured pretreatment serum VEGF levels from high-risk DLBCL 
patients. VEGF levels in circulating blood are known to be higher among cancer 
patients than healthy individuals. Many tumours produce large quantities of VEGF, 
and as a result, diagnosis and prognosis of cancer may be predicted by measuring 
changes in VEGF concentrations in blood. We observed that high s-VEGF levels 
were associated with poor performance status and high IPI score. This suggests that 
s-VEGF is an indicator of high tumour burden and rapid progression of the disease. 
Indeed, it has been shown that elevated VEGF levels correlate with higher number 
of involved areas and higher tumour burden in lymphoma (Rueda et al. 2007). 
Tumour growth is dependent on active angiogenesis stimulated by VEGF. Also, 
VEGF can stimulate vascular permeability enabling the dissemination of the disease. 
(Dvorak 2010)  Mouse models have demonstrated that engraftment of NHL 
correlates with tumour VEGF production, and targeting the VEGF pathway with 
neutralizing antibodies results in inhibition of tumour growth (Wang et al. 2004). 
Interestingly, there is evidence that VEGF is also important in establishing immune 
tolerance to cancers (Ellis et al. 2008). In lymphoma, VEGF has been shown to 
impair dendritic cell maturation (Cirone et al. 2008, Laxmanan et al. 2005) as well 
as directly inhibit the proliferation and cytolytic activity of effector T-cells (Wang et 
al. 2013). Therefore, high VEGF levels may play a role in allowing lymphomas to 
evade the induction of an immune response (Upadhyay et. al 2015). 
In our study, high VEGF levels served as an adverse prognostic factor in high-risk 
DLBCL patients treated with immunochemotherapy. These findings are in line with 
previous studies from the prerituximab era, and further suggest that the addition of 
rituximab to chemotherapy does not abolish the adverse impact of s-VEGF on the 
outcome. (Niitsu et al. 2002, Pedersen et al. 2005, Salven et al. 2000) However, we 
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could not observe the association of s-VEGF levels with OS. This might be due to 
efficient salvage therapies and a relatively high proportion of non-lymphoma deaths 
in this patient cohort (only 14 of the 21 deaths were lymphoma-related).  
We also used the gene expression array to study the relevance of the VEGF gene 
expression in the tumour. Although VEGF-levels in the circulation were associated 
with PFS, the VEGF gene expression levels did not correlate with survival nor with 
the serum results. In other words, a patient can have an extremely high level of 
VEGF in circulation while the tumour cells express the VEGF gene only remotely 
and vice versa. These results are in line with Lenz´s (2008a) stromal gene 
signatures: Even though the prognostically unfavourable stromal-2 signature 
reflected tumour blood vessel density and the genes encoding the key regulators of 
angiogenesis were highly expressed, VEGF was not among the genes overexpressed. 
Stromal-2 gene signature genes encode well-known markers of endothelial cells and 
regulators of angiogenesis such as VEGFR2 (VEGF receptor 2). This suggests a 
more complex interplay between malignant cells and TME leading to enhanced 
VEGF signalling. It is also possible that the tumour is responding, or becoming 
sensitized, to VEGF developed elsewhere in the body. In 2007, Gratzinger et al. 
found that DLBCL tumours showing higher local VEGF expression showed 
correspondingly higher VEGFR and MVD, implying that lymphoma cells induce 
local tumour angiogenesis and that there is an autocrine growth-promoting feedback 
loop. Also, in chemotherapy-treated patients high VEGF expression combined with 
high VEGFR expression in lymphoma cells has been connected to improved 
survival. (Gratzinger et al. 2008) It is important to distinguish between VEGF 
expression by the lymphoma cells, VEGF gene expression and circulating levels of 
VEGF measured in serum samples. Our results suggest that the VEGF in the 
circulation is not derived from the tumour itself but is a host reaction to lymphoma. 
The relationship, if any, between s-VEGF and local expression of VEGF by the 
lymphoma is unknown. In the 2007 meta-analysis, Kut et al. studied the distribution 
of VEGF in the body of cancer patients. Although the concentration of VEGF in the 
tumours was high, the total quantity of VEGF in the tumours and in the circulating 
blood was small compared to the muscles. This large reservoir of VEGF may have 
important treatment implications in the future. 
Anti-angiogenetic agents have been studied also in the DLBCL setting. The phase 
III MAIN trial compared Bevacizumab to placebo in combination with R-CHOP on 
previously untreated DLBCL patients. Bevacizumab did not increase the efficacy of 
the treatment; instead it increased adverse events and is therefore not evaluated 
further in DLBCL (Seymour et al. 2014).  In this light, our results also underline the 
complexity of this disease, although high VEGF serum levels refer to inferior 
survival, the mere targeting of the serum VEGF is not enough when the tumour is 
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indifferent to VEGF expression. Further studies are required to determine the origin 
of serum VEGF in DLBCL, but based on immunohistochemical stainings 
demonstrating that the intensity of the VEGF signal is more prominent in tumour-
associated non-malignant monocytic cells/macrophages than in lymphoma cells, it is 
plausible to speculate that elevated VEGF levels reflect the host response to 
aggressive lymphoma. Also, there is a growing understanding of the active role of 
myeloid cells in tumour growth and angiogenesis, and the data showing that VEGF 
in tumour tissue is primarily synthesized by inflammatory cells, especially by 
macrophages and mast cells (Murdoch et al. 2008, Squadrito et al. 2011).  
It is also established that the function of VEGF is not limited to angiogenesis and 
vascular permeability (Senger 2010). In mouse models VEGF can affect the function 
of immune cells in the TME and affect the host response to tumours (Hansen et al. 
2012) In addition to affecting endothelial and tumour cells VEGF influences tumour 
function by targeting other cell types in the tumour microenvironment. Notably, 
immune cells can express VEGF receptors, and the functions of these cells can be 
regulated by VEGF signalling. (Goel et al. 2013)  Macrophages in the TME secrete 
VEGF, which contributes to the many functions of VEGF in tumours (Galdiero et 
al.2013). It is evident that VEGF signalling in tumour cells affects tumour functions 
independently of angiogenesis, and interestingly, autocrine VEGF signalling can 
regulate the size of the cancer stem cell pool (Goel et al. 2013). 
7.3 TAMs 
From the evidence presented above, it becomes clear that the host inflammatory 
response to the tumour is at least partly regulated by the circulating immune cells 
that are able to migrate into the tissues, including tumour tissues. It is acknowledged 
that the TAMs play an important role in the angiogenesis. In experimental models, 
TAMs accumulate before the angiogenic switch and are necessary for the switch to 
occur (Lin et al. 2006). Therefore, we investigated the role of the TAMs in the 
prognosis of immunochemotherapy treated DLBCL. The results were similar in 
several patient sets: high TAM content in the tumour tissue resulted in superior 
survival in the immunochemotherapy-treated patient populations. However, in the 
case of lymphomas treated with a rituximab-containing regimen, the effect of 
CD68+ macrophages in the tumour tissue was opposite. 
In most cancers, including chemotherapy-treated DLBCL, high TAM content is 
considered an adverse prognostic marker (Wada et al. 2012, Nam et al. 2014). Our 
results were in contrast with this data. Therefore, it was tempting to speculate that 
the addition of rituximab into the equation abolishes the negative prognostic value of 
TAMs. We further performed an experiment in which the macrophage marker gene 
expressions and TAM counts in the tumour tissue were measured prior to and one 
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day after the first immunochemotherapy cycle. Significant increase in the TAM 
count was observed after the therapy suggesting that immunochemotherapy recruits 
macrophages into the lymphoma tissue. This result is in line with what is known 
about the mechanisms of action of rituximab and other monoclonal antibodies. They 
are known to induce ADCC, mediated by a variety of effector cells including 
macrophages, and also to recruit macrophages and NK cells by binding to their Fcγ 
receptors. (Weiner 2010) 
We also observed a correlation between serum levels of CCL18, a chemokine linked 
to M2 macrophages, and survival.  High levels of CCL18 have been reported in 
various cancers including gastric cancer (Wu et al. 2013) prostate cancer (Xu et al. 
2014) and lung cancer (Ploenes et al. 2013). Elevated s-CCL18 levels have also been 
reported in chronic infectious diseases such as arthritis (Schutyser et al. 2005).  In 
non-small cell lung cancer low levels of s-CCL18 have been connected with inferior 
survival (Ploenes et. Al 2013). High s-CD163 has been connected with inferior 
survival in multiple myeloma (Andersen et al. 2014). Although there are some 
reports of elevated s-CCL18 levels in cutaneous T-cell lymphomas, to our 
knowledge there are no prior publications of the s-CCL18 and s-CD163 levels and 
their correlation with survival in DLBCL. In our patient set, low CCL18 levels in 
circulating blood correlated with inferior survival. Also, patients with low s-CD163 
level tended to have inferior survival compared to those with higher levels. This may 
reflect a host inflammatory response to DLBCL. S-VEGF levels did not correlate 
with s-CCL18 levels suggesting they are not connected. CCL18 is constitutively 
present at high levels in circulation and likely contributes to the physiological active 
recruitment of lymphocytes and dendritic cells under inflammatory and pathological 
conditions. Therefore, it has a crucial role in the generation of primary immune 
responses. (Schutyser et al. 2005) CCL18 has also been shown to be able to 
stimulate monocytes to mature into macrophages. (Schraufstatter et al. 2012) It is 
tempting to speculate that low levels of TAMs might be a consequence of low s-
CCL18, both contributing to inferior survival in immunochemotherapy treated 
patients. Inferior survival was also observed in patients with low s-CCL18 levels 
after three courses of immunochemotherapy. More studies are needed to define if 
this is due to inadequate or insufficient host inflammatory response to therapy. 
The results are interesting since they suggest that TAMs exhibit a dual role in the 
pathogenesis of DLBCL and this role is treatment-specific. The prognostic 
implication of TAMs does appear to be dependent on the administration of anti-
CD20-directed antibodies. (Figure 12) The data allow the speculation that TAMs 
can switch from a tumour-promoting to a tumour-inhibiting function in response to 
rituximab. Similarly, the prognosis of FL has been shown to be dependent on the 
chemotherapy used. (de Jong et al. 2009) The results are in line with the work of 
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Nam et al. (2014) in which a high count of CD68+ macrophages correlated with 
superior survival. On the other hand, in the work of Nam et al. the count of CD163+ 
macrophages correlated with inferior survival whereas in our study such correlation 
was not found. Our results also mirror similar observations made in FL by Taskinen 
et al. (2007) and Canioni et al. (2008). On the basis of these results it can be 
speculated that rituximab has potential to recruit TAMs and convert their role from 
pro-tumour into anti-tumour. TAMs are a potential treatment target in lymphoid 
malignancies. Also, a new generation of CD20-antibodies is undergoing clinical 
trials and new studies are needed to address the question whether the prognostic 
value of macrophages holds true for new drugs. The mechanism by which 
macrophages are recruited into the DLBCL microenvironment remains unknown. In 
FL, stromal cells have been shown in vitro to secrete CCL2, thereby recruiting 
monocytes and differentiating them into a tumor-promoting phenotype (Guilloton et 
al. 2013). Similar studies are currently lacking in DLBCL. Future studies are needed 
to fully understand the impact of rituximab-containing treatment regimens on 
tumour microenvironment interactions in DLBCL. 
 
Figure 12 The prognostic role TAMs appears to be dependent on the administration of 
anti-CD20-directed antibodies. (Riihijärvi et. al. 2015) 
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7.4 Future perspectives 
Our results highlight the complex interplay between malignant cells, tumour 
microenvironment and inflammatory host responses. PKCβII expression reflects the 
interplay between tumour signalling and the microenvironment. High s-VEGF levels 
represent high tumour burden in the body associated with inferior survival. High 
TAM count and high s-CCL18 levels may reflect host attributes in response to 
lymphoma. These features can be favourable or unfavourable, depending on the 
therapy used. Patient populations in our studies were quite small and these findings 
need to be re-evaluated in prospective studies. Novel immunotherapeutic agents are 
likely to alter the significance of many prognostic factors defined in the rituximab-
era providing new insight in lymphoma biology. Rapidly advancing field of cancer 
immunology is producing new promising treatment modalities. These 
immunotherapies target to increase the strength of host immune responses against 
tumour tissue. In the future, DLBCL treatment decisions will be customized and 
based on molecular subtypes defined by host and tumour characteristics. 
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8 
8 Summary 
1. High PKCβII expression in DLBCL tumour is an adverse prognostic marker 
when patients are treated with immunochemotherapy. 
2. High serum VEGF levels correlate with poor prognosis in 
immunochemotherapy-treated patients. VEGF gene expression does not, 
however, correlate with the prognosis or serum VEGF levels suggesting that 
the serum levels are not derived from the tumour tissue and may be a host 
response instead. 
3. MVD in DLBCL tissue does not have prognostic relevance when patients are 
treated with immunochemotherapy. 
4. High TAM content correlates with good prognosis in immunochemotherapy-
treated DLBCL patients. Reversely, when patients are treated with 
chemotherapy, high TAM content correlates with inferior survival. 
5. Serum levels of CCL18 are associated with survival in DLBCL patients 
treated with immunochemotherapy. 
Further studies are needed to validate the results in larger patient populations. 
Together, the results underline the complex biology of DLBCL. Malignant cells are 
in a constant interplay with the tumour microenvironment and this interplay may 
offer novel therapeutic options in DLBCL. 
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